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ABSTRACT 
 
 
Alshahrani, Saeed. M.S., Department of Pharmacology and Toxicology, Wright State 
University, Boonshoft School of Medicine 2012. Role of NKCC co-transporters in 
insulin secretion.  
 
 
 
        The maintenance of high intracellular chloride concentration ([Cl–]i) in insulin-
secreting pancreatic β-cells plays an important role in glucose-induced depolarization and 
insulin secretion. Glucose promotes the electrogenic efflux of Cl– contributing to β-cell's 
electrical and secretory activity. The solute carrier family 12 group A member 1 
(Slc12a1) and 2 (Slc12a2) encode several splice variants of the kidney-specific and the 
ubiquitous isoforms, respectively, of bumetanide (BTD)-sensitive Na+-dependent K+2Cl– 
co-transporters. The Slc12a2 co-transporter, also known as NKCC1, is involved in the 
maintenance of a high [Cl–]i in β-cells and its pharmacological inhibition impairs insulin 
secretion in response to glucose in vivo and in vitro. The present study shows that mice 
lacking both functional alleles of the Slc12a2 gene (NKCC1 KO) have better fasting 
glycaemia and improved glucose tolerance when compared to wild-type mice (NKCC1 
WT). These observations correlated with increased insulin secretion in response to 
glucose in vivo and in vitro and with increased β-cell mass. Moreover, administration of 
BTD to NKCC1 KO mice worsened their glucose tolerance. This effect of BTD in vivo 
correlated with a direct inhibition of insulin secretion by BTD from islets lacking 
functional Slc12a2 genes, therefore suggesting the presence of a BTD-sensitive 
mechanism involved in insulin secretion, which is different from Slc12a2. Molecular 
 
 
iv 
expression analysis demonstrates that β-cells express a specific splice variant of the 
kidney-specific BTD-sensitive Slc12a1 gene i.e., NKCC2A. Altogether, our results 
provide for the first time evidence for a functional role of this co-transporter on insulin 
secretion.       
 
         Conclusions: 1) Functional alleles of the Slc12a2 gene are not necessary for insulin 
secretion. 2) Bumetanide impairs insulin secretion and glucose homeostasis in vivo. 3) 
Bumetanide impairs insulin secretion by a direct effect on insulin secreting β-cells. 4) 
Pancreatic β-cells express specific splice variants of Slc12a2 and Slc12a1 i.e., NKCC1a 
and NKCC2A. 
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1- INTRODUCTION  
Diabetes Mellitus  
  Diabetes mellitus is a poly-endocrine and metabolic disorder characterized by 
chronic hyperglycemia along with disturbances of carbohydrate, fat and protein 
metabolism (Ostenson 2001). This syndrome results from either defect in insulin 
secretion or insulin action or both. According to the American Diabetes Association, 25.8 
million children and adults in the United States are suffering from diabetes, meaning that 
~8.3% of the population have diabetes (Zhang 2011). Worldwide, the total number of 
individuals suffering from diabetes is projected to increase to 366 million in 2030. I fact, 
the World Health Organization (WHO) has established recently that one out of 10 adults 
worldwide has diabetes (www.who.int/mediacentre/factsheets/fs312/en/index.html). 
According to the International Diabetes Federation, diabetes mellitus in 2003 was the 
fourth leading cause of death in most developed countries (www.idf.org/diabetesatlas). 
        Diabetes mellitus is categorized in three types. On one hand, type I diabetes (T1D), 
also known as insulin dependent diabetes mellitus (IDDM) or juvenile onset diabetes, is a 
relatively less common chronic metabolic disorder caused by β-cell destruction that leads 
to absolute insulin deficiency. It requires insulin treatment constantly. On the other hand, 
more than 85 % of all diabetic individuals are diagnosed with diabetes mellitus type II 
(T2D). T2D is characterized by relative insulin deficiency due to low insulin secretion 
rates or due to tissue resistance to the action of the hormone or a combination of both. 
Characteristically, T2D ultimately endures due to dysfunction of the β-cells in the 
pancreatic islets of Langerhans and due to a failure to provide enough insulin to supply 
 
 
2 
tissue demands. The third type of diabetes, gestational diabetes mellitus, occurs during 
pregnancy (DeFronzo 2004).  
 Currently, the only available treatment for T1D is administration of exogenous 
insulin. Thus, T1D patients have to constantly monitor and observe their glucose levels 
and inject insulin whenever required, always after meals. Lack of control can result in 
either hypoglycemia, which can cause a coma (Katz, et al. 2012), or hyperglycemia, 
which increases the risk of developing diabetic complications such as blindness, kidney 
failure, amputations, and other complications (Cowie, et al. 1989; Icks, et al. 1997). On 
the contrary, T2D is a more complex metabolic disorder usually found in combination 
with obesity, impaired β-cell function (Kloppel, et al. 1985), increased endogenous 
hepatic glucose output and insulin resistance in target tissues (Kolterman, et al. 1981; 
Leahy 2005). Although the relative contribution and interaction of all of these defects in 
the pathogenesis of T2D remains to be clarified (Cerasi 1995), therapeutic options are 
aimed at improving β-cell or tissue sensitivity to glucose or insulin (Gerich 2002b). 
Therefore, studying and elucidating the mechanisms involved in insulin secretion is of 
capital relevance at the time of taking new therapeutic avenues to improve β-cell 
function.    
 
Synthesis and function of insulin  
 Insulin secretion from β-cells, a major part of islets of Langerhans, involves the 
intimate dialogue between several external and internal signals. Thus, neurotransmitters, 
hormones, nutrients, and drugs all stimulate or reduce insulin release (Ashcroft and 
Rorsman 2012). Most of our knowledge regarding the molecular and functional 
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mechanisms involved in insulin secretion in response to glucose comes from in vivo and 
in vitro experiments performed during the last 50 years [(Chou and Ipp 1990; Porksen, et 
al. 2002; Smith, et al. 1990; Sturis, et al. 1994) and references therein]. Insulin is the only 
hypoglycemic hormone of the organism (Rorsman, et al. 2000). Therefore, secretion of 
insulin prevents hyperglycemia. Indeed, insulin reduces glycaemia by promoting glucose 
uptake in tissues like adipose and muscle tissue, increasing glycogen synthesis and 
inhibiting glucose release from glycogen storages, a process known as gluconeogenesis 
(Jensen and Richter 2012).  
 Insulin is synthesized in the rough endoplasmic reticulum (ER) of β-cells as pre-
pro-insulin, a 110 amino acid polypeptide product of the translation of the insulin gene. 
Pre-pro-insulin is converted to pro-insulin by the action proteases. These proteases cleave 
the signal peptide to generate pro-insulin, which begins to be packaged in the trans‐Golgi 
network and sorted into immature secretory granules (Fig. 1). The ATP‐dependent H+ 
pump acidifies these immature granules and pro-insulin undergoes proteolytic cleavage 
resulting the formation of mature insulin and C‐peptide in equal molar quantities. During 
maturation of granules, insulin concentrates and crystallizes with Zn2+ and Ca2+ ions to 
form the characteristic dense‐core granules of β-cells (Chausmer 1998). These mature 
insulin-containing granules constitute two functionally different insulin pools, one that is 
composed by granules that are readily releasable and another that is considered a reserved 
pool [reviewed in (Hou, et al. 2009)]. These two different insulin-containing granule 
populations are thought to be responsible for the biphasic nature of insulin release (Hou 
et al. 2009). Indeed, the granules close to or associated with the plasma membrane are the 
ones that are subjected to acute Ca2+‐dependent release, accounting for first phase insulin 
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secretion (see bellow). On the contrary, the second phase of insulin secretion requires 
trafficking of reserved granules to the plasma membrane plus de novo insulin 
biosynthesis (Hao, et al. 2005; Hou et al. 2009; Rorsman and Renstrom 2003). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
!
 
  
Figure 1: Insulin biosynthesis. Pre-pro-insulin is synthesized 
from the insulin gene and directed into the endoplasmic reticulum 
by the signal sequence, where it folds into a suitable conformation 
through disulfide bonds (SS). The signal sequence is then 
removed, and pro-insulin is further processed in the Golgi 
apparatus where the C-peptide is removed and mature insulin 
produced.   
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Phases of insulin secretion 
 Insulin secretion is stimulated primarily by glucose metabolism within the β-cell 
(Rorsman and Renstrom 2003). Insulin is secreted in response to glucose in a well-
defined fashion (Rorsman et al. 2000). Two phases of insulin secretion have been 
identified. The first phase is a rapid or acute release of insulin stored in intracellular 
granules of the β-cell located closely to the plasma membrane (Barg, et al. 2002; 
Rorsman and Renstrom 2003). This phase is defined as the initial burst of insulin, which 
is secreted in the first 5-10 min after β-cells exposure to increased glucose (Caumo and 
Luzi 2004). The first-phase of insulin secretion is followed by the second-phase, which 
involves de novo synthesis of insulin (Hou et al. 2009). Under normal physiological 
conditions, this phase is sustained and lasts until normoglycaemia is reached (Caumo and 
Luzi 2004) (Fig. 2). Impairment of first-phase insulin secretion is one of the earliest 
manifestations of T2D (Gerich 2002a, b). Once established, impairment of the first phase 
of insulin secretion negatively impacts glucose tolerance and carbohydrate metabolism, 
and therefore T2D endures (Guillausseau, et al. 2008).  
 The second phase of insulin secretion is sustained and relatively slow when 
compared to the first phase. It involves insulin stored in reserve granules and the 
coordinated de novo biosynthesis of insulin. This phase of insulin secretion is frequently 
impaired in both, patients with T2D and high-risk populations (Del Prato, et al. 2002; 
Gerich 2002a, b). However, it is the impairment of the first phase of insulin secretion the 
necessary defect in all conditions of impaired glucose regulation (Del Prato et al. 2002). 
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Mechanisms of insulin secretion 
 The primary mechanism of insulin secretion involves electrical activity in β-cells 
in response to increased blood glucose level i.e., glycaemia. The best-characterized 
pathway whereby glucose promotes electrical activity in insulin secreting β-cells involves 
membrane glucose transporters (GLUT1 in humans or GLUT2 in rodents) that facilitate 
glucose entry (Rorsman and Renstrom 2003). Once transported, glucose is 
phosphorylated and metabolized via glycolysis increasing the ATP/ADP ratio. ATP-
sensitive K+ (KATP)-channels in normal conditions are open to maintain the membrane 
!
 
 
Figure 2: Phases of insulin secretion. Top figure shows the two 
characteristic phases of insulin secretion. First phase happens 5-10 
minutes post-glucose stimulation, whereas the second phase is 
sustained and takes about 1-2 hours.  Bottom figure shows the 
characteristic insulin secretion pattern observed in T2D line. First 
phase is absent. 
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potential around −70 mV (Drews, et al. 2010). Increase in the ATP/ADP ratio in β-cells 
results in closure of KATP-channels and the consequent gradual decrease in K+ 
conductance, which depolarizes the β-cell. This depolarization gates voltage-dependent 
L-type Ca2+ channels promoting Ca2+ influx and triggering exocytosis of stored insulin 
granules (Drews et al. 2010).  
 
The ATP-dependent K+-channels  
 Clearly, KATP-channels integrate and transduce glucose-generated metabolic 
signals that culminates in membrane depolarization Ca2+ action potentials and insulin 
secretion (Fig. 3). KATP-channels are the targets for sulfonylureas, which are commonly 
prescribed oral agents for the treatment of T2D. The sulfonylureas, like glucose, close 
KATP channels thus stimulating insulin secretion. The KATP-channels expressed in β-cells 
are octameric complexes of two different units: the sulfonylurea receptor (SUR-1) and an 
inward rectifier K+-channel (Kir6.2). SUR-1 not only binds sulfonylureas but also ATP 
and therefore SUR-1 belongs to a superfamily of ATP-binding cassette proteins. ATP 
also binds Kir6.2, the pore that conducts K+. Interestingly, sulfonylureas require the 
presence of glucose to emulate the insulinotropic effects of glucose i.e., the plasma 
concentrations of glucose that stimulate insulin secretion (Henquin 1998). Therefore, 
additional mechanisms are present in β-cells allowing them to depolarize and secrete 
insulin when K+-channels are closed [reviewed in (Henquin, et al. 2009)]. 
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Figure 3: The ATP-dependent K+-channels. A) Under low 
metabolic conditions, ATP-dependent K+-channels are open 
keeping the β-cell hyperpolarized. B) When plasma glucose 
increases, it is transported into the β-cell and metabolized 
resulting in increased ATP/ADP ratios leading to the closure 
of ATP-dependent K+-channels, membrane depolarization, 
Ca2+ influx and insulin secretion from stored granules.  
 
 
9 
       In spite of the fact that KATP-channels transduce glucose signals into insulin 
secretion, functional deletion of the genes encoding for subunits of these channels in mice 
result in minimal changes in insulin secretion or remains unaffected regardless of glucose 
levels, even under constant depolarization and bursts of Ca2+ action potentials (Best, et al. 
2010). In humans, however, mutations in SUR-1 have been associated with congenital 
hyperinsulinism; a rare disorder characterized persistent hyperinsulinemic hypoglycemia 
(De Vroede, et al. 2004). Although SUR-1 mutations in mouse may not resemble the 
human conditions, mice β-cells may potentially have redundant or additional mechanisms 
involved in insulin secretion in response to glucose (Henquin et al. 2009). 
 
The VRAC hypothesis 
 There is no doubt that KATP-channels play an important role in insulin secretion 
(Henquin et al. 2009). Yet, in addition to the well-known KATP-channel-dependent 
pathway, physiological concentrations of glucose can still promote β-cell's electrical 
activity and insulin secretion even in the absence of functional KATP channel activity 
(Best 2002; Best et al. 2010; Best, et al. 1992; Seghers, et al. 2000). The presence of 
KATP-channel-independent pathways used by β-cells to secrete insulin was inferred from 
the fact that low non-insulinotropic or normal concentrations of glucose i.e., 2.5 and 5 
mM, respectively, inhibit KATP-channel-mediated 42K+ or 86Rb+ efflux from islets whereas 
higher insulinotropic glucose concentrations i.e., >7.5 mM stimulate efflux (Lindstrom, et 
al. 1988; Lindstrom, et al. 1986).  Since the opening of K+-channels of any molecular 
nature is predicted to hyperpolarize the membrane potential, it is clear that glucose-
induced insulin secretion happens due to activation of other ionic conductance, which is 
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not related to K+. Moreover, KATP-channel activity is inhibited or marginally present in 
the presence of low concentrations of glucose (2.5-5 mM) and disappears at higher 
glucose concentrations (Best et al. 2010). Thus, Len Best and co-workers have proposed 
the concept that KATP-channels become activated at low glucose concentrations, for 
instance, under starvation conditions, therefore hyperpolarizing the β-cell thereby 
preventing insulin release. This explains why hypoglycemia does not happen under 
normal fasting conditions and provides the basis for the proposition that additional K+-
independent ionic mechanisms involved in insulin secretion are present in β-cells (Best et 
al. 2010). 
  
 
!
 
 
Figure 4. The VRAC Hypothesis. Glucose enters β-cells via Glucose transporter 2 
(GLUT2). Then, glucose is metabolized in Krebs cycle leading to increased ATP/ADP 
ratio and intracellular osmolarity (right section). This increase in β-cell osmolarity 
transiently increases cell volume which results in increased Cl– via volume activated Cl– 
channels leading to plasma membrane depolarization independently of K(ATP)-channels. 
Depolarization of the β-cell opens voltage-dependent Ca2+ channels promoting Ca2+ influx 
and triggering insulin release from stored granules. A high [Cl–]i  in β-cells ensures this 
mechanism. NKCC1 is considered the main transporter involved in the maintenance of a 
high [Cl–]i in β-cells. 
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           This additional KATP-channel-independent glucose-sensing mechanism in β-cells 
involves glucose-induced electrogenic Cl− efflux through a volume-regulated anion 
channel (VRAC), a concept originally hinted by Sehlin in 1978 after the observation that 
a rise in glucose concentration stimulated 36Cl– efflux from pre-loaded mouse islets 
(Sehlin 1978). This concept was subsequently corroborated in different β-cells from 
several species and has set the stage for the VRAC hypothesis to explain K+-independent 
insulin secretion (Best et al. 2010), as explained in Figure 4. 
 Although the mechanisms whereby glucose activates the VRAC remain largely 
unknown, it is believed that cell swelling induced by glucose itself and its metabolites 
such as lactate may play a role in VRAC activation (Best et al. 2010). Independently of 
the mechanisms of VRAC activation, electrogenic Cl− efflux is possible because the 
intracellular chloride concentration ([Cl–]i) of β-cells is maintained higher than it would 
be expected if Cl– ions were distributed across the plasma membrane strictly according to 
the Nernst's equation. Indeed, fluorometric methods have determined that [Cl–]i in β-cells 
is 34 mM, which is higher than expected from a passive distribution (Eberhardson, et al. 
2000). Therefore, an inward transport of Cl– against its electrochemical gradient must be 
present in β-cells (Fig. 4). This Cl– transport mechanism was identified as the BTD-
sensitive Na+K+2Cl– co-transporter 1 (NKCC1) (Best 2005; Majid, et al. 2001). The 
relevance of NKCC1 in glucose-induced insulin secretion is evidenced by the fact that 
both bumetanide (BTD) and furosemide, two potent diuretics inhibitors of NKCC, 
directly block glucose-induced insulin secretion (Best 2005; Sandstrom 1990). These 
findings have provided support to the suggestion that loop-diuretics may have 
diabetogenic consequences (Furman 1981). However, these results were not obtained by 
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other investigators (Giugliano, et al. 1980; Robinson, et al. 1981) and thus, it remains 
controversial weather or not BTD impairs glucose homeostasis. 
 
BTD and carbohydrate metabolism 
 The VRAC hypothesis explains why loop-diuretics such as BTD and furosemide 
impair insulin secretion in vitro or in vivo (Sandstrom 1988, 1990). Indeed, as mentioned 
above, Na+K+2Cl– co-transporters (NKCCs), the main carriers involved in the 
maintenance of high [Cl–]i are the targets of BTD (Gamba 2005). 
 It is important to mention that most of BTD is concentrated and eliminated in its 
intact form by the kidney, a situation that ensures high concentrations of the drug in the 
tubular lumen (Cohen, et al. 1976) where the kidney-specific isoform of the NKCCs i.e., 
NKCC2 is expressed. Therefore, BTD is a potent diuretic used to treat edema associated 
to heart failure and hypertension (Garg, et al. 2007). Low concentrations of BTD, 
however, are being used to treat neonatal seizures in the immature brain expressing 
relatively high levels of one of the two known isoforms of the NKCCs: NKCC1 (Kahle, 
et al. 2009). Inhibition of NKCC1 in immature neurons reduces Cl– influx keeping 
GABA-mediated actions more hyperpolarizing (Kahle et al. 2009). In the β-cell, these 
non-diuretic low doses of BTD may not impact insulin secretion. However, the impact of 
BTD on [Cl–]i  in β-cells may depend on the relative expression levels of NKCCs relative 
to other Cl– carriers as well as to the presence of polymorphic alleles of these 
transporters. Indeed, it has been recently shown that NKCCs exists as several 
polymorphic variants (Fox, et al. 2007; Hiller, et al. 2006; Vrabec, et al. 2008; Walsh, et 
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al. 2011), raising the possibility that some of them may have the potential to be more or 
less sensitive to BTD than others.  
 This concept may help explain the apparently contradictory results related to the 
role of BTD on glucose homeostasis in normal individuals. Indeed, in some studies BTD 
impairs glucose tolerance, in others it improves or does not have an affect. For instance, 
Giugliano et al. showed that chronic BTD treatment had no effect on insulin levels, but it 
did increase glucose tolerance in humans. Furthermore, these authors suggested that BTD 
could be even used as treatment of diabetes (Giugliano et al. 1980).  On the contrary, 
Robinson et al. showed a negative impact of BTD on basal insulinemia with no effect in 
glucose tolerance in human (Robinson et al. 1981). In other mammals, such as dogs, rats 
and mice, similar controversial results were obtained with BTD. For instance, the study 
of Hermansen et al. showed that BTD has no effect in insulin secretion in pancreatic β-
cells isolated from dogs (Hermansen, et al. 1985) whereas Sandström showed that BTD 
does inhibit insulin secretion by a direct effect of β-cells (Sandstrom 1988, 1990). 
Therefore, based on the current knowledge regarding the role of diuretics in insulin 
secretion, the apparently disparate effects of BTD on insulin secretion and glucose 
homeostasis might be related to differences in expression of its targets e.g., NKCC1 
splicing or allelic variants as well as unknown BTD targets. 
  
The Slc12A family of cation-coupled chloride-co-transporter  
 The [Cl–]i is regulated by Cl– carriers and channels present in the plasma 
membrane (Alvarez-Leefmans and Delpire 2009). All members of the solute carrier 12 
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group A (Slc12a) family of cation-coupled chloride-co-transporter are directly involved 
in the regulation of [Cl–]i. This family of co-transporters includes Na+-K+-2Cl– (Slc12a1-
2) Na+-Cl– (Slc12a3) and K+-Cl– (Slc12a4-7) co-transporters (NKCCs, NCC and KCCs, 
respectively). Topologically, these co-transporters are considered to share similar 
structures consisting in 12 membrane-spanning segments and two intracellular N- and C-
termini [reviewed in (Di Fulvio and Alvarez-Leefmans 2009)] (Fig. 5). Functionally, 
NKCCs and NCCs are transport mechanisms that accumulate Cl– in cells using the 
energy stored in the Na+, K+ and Cl– chemical gradients, whereas KCCs mediate Cl– 
extrusion driven by the products of the K+ and Cl– gradients (Adragna, et al. 2004; 
Gamba 2005). Pharmacologically, NKCCs and NCCs are distinguished based on their 
inhibitory profiles to diuretics. Indeed, BTD is a potent inhibitor of NKCCs whereas 
NCCs are relatively insensitive to this drug. Conversely, NCCs are specifically inhibited 
by thiazides whilst NKCCs are not. With the exception of D4, which is a specific 
inhibitor of KCC2 (Austin and Delpire 2011), no specific pharmacological inhibitors of 
KCC1, KCC3 and KCC4 are available (Adragna et al. 2004). 
   
!
 
 
Figure 5: Slc12A family of cation-coupled chloride-co-transporters. This figure shows 
the different ways of ion transport through cell membrane via NKCC, NCC and KCC. 
NKCC transports Na+, K+, and 2Cl– ions, whereas NCC does not transport K+. KCC 
transport K+ and Cl– outside the cell, which is just opposite what NKCC and NCC do.  
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Slc12a2 (NKCC1) and Slc12a1 (NKCC2) 
 Two NKCC isoforms (NKCC1 and NKCC2) encoded by two different genes 
Slc12a2 and Slc12a1, respectively, have been identified (Di Fulvio and Alvarez-
Leefmans 2009). NKCC1 is a ubiquitously expressed co-transporter whereas NKCC2 is 
not. NKCC1 is involved in the maintenance of [Cl–]i above electrochemical equilibrium 
and, in virtue of its high capacity to transport water (Hamann, et al. 2010), NKCC1 
directly regulates cell volume in all cells tested so far (Hoffmann, et al. 2009). Under 
basal isotonic conditions, NKCC1 is considered marginally active but it becomes 
activated in osmotically shrunken cells, resulting in a net gain of K+-Cl– and water 
thereby restoring the original cell volume [regulatory volume increase (RVI)] (Gagnon 
and Delpire 2010; Hoffmann et al. 2009) (Fig. 6). It is known that transient osmotic 
changes in cell volume regulate ion channels and transporters, including NKCC1 
(Hoffmann et al. 2009). However, cell volume changes also regulate kinases and 
phosphatases. Further, cell volume changes impact the organization of intracellular 
organelles (Lee and Linstedt 1999) intracellular trafficking of proteins (Reinehr and 
Haussinger 2007), hormone secretion (Best et al. 2010), cell growth and proliferation 
(Stutzin and Hoffmann 2006).  
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  A detailed analysis of the mammalian Slc12a family of genes has been published 
(Di Fulvio and Alvarez-Leefmans 2009). Here, we will briefly analyze some of them. 
The mouse Slc12a2 gene produces two variants: mNKCC1a (RefSeq: NM_009194) and 
mNKCC1b lacking exon 21 (Strausberg, et al. 2002). The rat Slc12a2 gene may produce 
two splice variants as well. However, only rNKCC1a variant has been cloned 
(AF051561) (Moore-Hoon and Turner 1998). The human SLC12A2 gene produces at 
least three variants: hNKCC1a (U30246, AY280459) (Liedtke and Cole 2000; Strausberg 
et al. 2002), hNKCC1b (BC144221 and BC146839) and hNKCC1c (BC033003) (Fig. 
7A). Two coding exons are involved in the generation of potential hNKCC1variants: 
exon 21 and exon 26. Like in the mouse, absence of exon 21 in hNKCC1 mRNAs 
predicts hNKCC1b. The 26th exon of the human SLC12A2 gene contains an internal 
 
Figure 6: Regulatory volumes increase 
and decrease (RVI & RVD). This figure 
shows that NKCC is involved in 
regulatory volume increase followed by 
cell shrinkage due to hypertonicity, 
whereas KCC does the opposite job and 
is involved in regulatory volume 
decrease following cell swelling. Figure 
adapted from (Kahle, et al. 2008). 
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splicing acceptor site that divides the exon in two coding parts: exon 26a and 26b. 
Inclusion of the whole exon 26 (a+b) generates hNKCC1c. Unlike hNKCC1b, hNKCC1c 
has been cloned; it is predicted to encode a protein of 1151 amino acids with the unique 
C-terminal sequence FYEPC as a consequence of including the first 66 bp of the 26th 
exon (exon 26a). In spite of the fact that the role of NKCC1 in cell volume regulation is 
well established, the relative contribution of each NKCC1 splice variant to this task 
remain unknown. Further, the expression pattern and tissue distribution of hNKCC1b and 
hNKCC1c remains to be determined. 
         Contrary to NKCC1, the products of the Slc12a1 gene (NKCC2) are considered 
kidney-specific, and as such, the function of NKCC2 has been established: it absorbs ~30 
% of the NaCl filtered by the glomeruli (Ares, et al. 2011). NKCC2s are 1095 amino acid 
proteins with a predicted core molecular mass of ~120 kDa. The main difference between 
NKCC2 variants locates in the amino acid sequence responsible for coding the second 
putative trans-membrane (TM2) domain and part of the intracellular loop connecting 
TM2-TM3 (see below), a region critically involved in ion transport (Gagnon and Delpire 
2010). The importance of NKCC2 in kidney physiology is exemplified by mutations of 
this co-transporter, which result in neonatal Bartter's syndrome type I, a disorder 
characterized by severe dehydration, polyuria, electrolyte imbalance, and decrease blood 
pressure (Simon, et al. 1996). Interestingly, NKCC2 has been recently found expressed 
outside the kidney (Akiyama, et al. 2010; Akiyama, et al. 2007; Gavrikov, et al. 2006; 
Kakigi, et al. 2009; Nickell, et al. 2007; Nishimura, et al. 2009). The functional impact of 
NKCC2 in extra-renal tissues remains unknown. 
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  As mentioned, the members of the Slc12a family of genes (Fig. 8) are expressed 
as several splice variants. In the mouse, three splice variants of NKCC2 are known: 
mNKCC2A (variant 1, U20973), mNKCC2B (variant 2, U20974) and mNKCC2F 
(variant 3, U20975) (Igarashi, et al. 1995) (Fig. 7B). They differ by the inclusion of one 
of three mutually exclusive exons: exon 4 (B), 5 (A) and 6 (F) i.e., the ones encoding for 
the amino acid differences in TM2-TM3. Similar variants have been cloned from the 
rabbit kidney (Payne and Forbush 1994). In the case of the rat, two variants have been 
cloned from kidney: Slc12a1 variant 3 [rNKCC2F, U10096 (Gamba, et al. 1994)] and 
Slc12a1 variant 1 [rNKCC2A, BC087017 (Strausberg et al. 2002)]. Although the human 
Slc12a1 gene has the potential to produce several splice variants, only one has been 
 
!
 
 
Figure 7: NKCC1 and NKCC2 splicing variants. A) NKCC1a (with no 
splicing in its exons) have been cloned from mice, rat and human 
sources, NKCC1b lacks exon 21 (brown). NKCC1c includes exon 26  
(a+b). B) NKCC2 has three different splice variants: NKCC2A, B and F 
includes exon 5 (green), 4 (blue) or 6 (brown), respectively (see text).      
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cloned from kidney: hNKCC2F [U5813 (Simon et al. 1996)]. 
 
 The study of NKCC2 function relied heavily on heterologous expression systems 
such as the Xenopus oocyte (Zeuthen and Macaulay 2012). This is partially due to the 
consensus notion that NKCC2 is absent in mammalian cell lines. Furthermore, NKCC2 
has been proven to be difficult to express and/or functionally detect in cell lines 
(Hannemann, et al. 2009). Therefore, assessing NKCC2 function in a mammalian cell 
context has been hampered by the lack of a mammalian cell model expressing 
endogenous NKCC2. Although success has been recently achieved in transfecting full-
length constructs of NKCC2 in some cells (Benziane, et al. 2007; Zaarour, et al. 2011; 
Zaarour, et al. 2009), the functional assessment of over-expressed NKCC2 may not 
always correlate with its functional properties when endogenously expressed. 
 
Animal models to study impact of NKCC on glucose homeostasis 
 Several animals model lacking functional NKCC1 have been established (Delpire, 
et al. 1999; Flagella, et al. 1999; Pace, et al. 2000). Different strategies have been 
followed to knockout Slc12a2 gene expression and function in mice. Regardless of the 
strategy followed to generate NKCC1 null-mice or knockout mice (NKCC1 KO), these 
mice share common phenotypic features. For instance, they have head imbalance 
movements, circling and spinning behavior and apparent hyperactivity associated with 
complete deafness. These behaviors are characteristic of inner-ear dysfunction (Delpire et 
al. 1999; Flagella et al. 1999; Pace et al. 2000).  
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 In spite of the importance of NKCC in the maintenance of [Cl–]i  and the known 
role of [Cl–]i in insulin secretion in vivo and in vitro, glucose homeostasis in NKCC1 KO 
mice was never addressed. The present project sprouted in our lab during the 
performance of behavioral tests of nociception using NKCC1 KO mice (Alshahrani, et al. 
2012). We observed that these mice were aggressive, shaky and wobbly, particularly after 
few hours of food deprivation. These clear, albeit unexpected signs of hypoglycemia 
prompted us to investigate the role of functional inactivation of NKCC1 on insulin 
secretion and glucose homeostasis.  
!
 
 
Figure 8: Gene mutation disease of Slc12A family of cation-coupled chloride-co-
transporter. Mutation in NKCC1 lead to broad effects like deafness, infertility, 
imbalance and other manifestations as explained above. NKCC2 mutations cause 
Bartter’s syndrome.   
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2- HYPOTHESES AND SPECIFIC AIMS  
Hypotheses  
1. Mice lacking functional alleles of NKCC1 have impaired insulin secretion in 
response to glucose. 
2. Bumetanide, a diuretic and potent inhibitor of NKCC1 impairs insulin secretion in 
vivo and in vitro. 
 
Specific aims  
1. To determine the role of NKCC1 in insulin secretion and glucose homeostasis in 
vivo in mice lacking both functional alleles of the Slc12a2 gene (NKCC1 KO).  
2. To determine the role of low, non-diuretic doses of bumetanide on insulin 
secretion in vivo in Slc12a2 gene targeted mice and in vitro in pancreatic islets 
and β-cell lines. 
3. To determine the molecular identity and pattern of expression of bumetanide-
sensitive co-transporters in islets and β-cell lines. 
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3- MATERIAL AND METHODS   
3.1 Materials  
3.1.1. Enzymes, kits and chemicals 
       Pfx polymerase, RNase-OUT, SuperScript-III reverse transcriptase, random 
hexamers, Lipofectamine2000 transfection reagent were from Invitrogen (Carlsbad, CA); 
dNTPs, alkaline phosphatase and exonuclease I were from Affimetrix/USB (Cleveland, 
OH); custom primers were from Integrated DNA Technologies (Coralville, IA); the 
RNeasy mini kit was from Qiagen (Valencia, CA). General chemicals were from Sigma 
(Saint Louis, MO). Tissue culture media, serum and supplements were from Fisher. 
Microscopy supplies were from Electron Microscopy Sciences (Hatfield, PA). 
3.1.2. Antibodies 
        Monoclonal antibodies against the C-terminal region of human NKCC1 (T4c) were 
from Developmental Studies Hybridoma Bank, University of Iowa. Rabbit anti human 
NKCC1 and β-actin antibodies were from Cell Signaling Technology (Danvers, MA). 
Anti-NKCC2 antibodies were a kind gift from Dr. Pablo Ortiz (Henry Ford Hospital, 
Detroit MI). Conjugated secondary antibodies for immunofluorescence application or 
Western blotting were from Jackson Immunoresearch (West Grove, PA). 
3.1.3. Animals 
        The studies involving genetically engineered mice were approved by the 
Institutional animal care and used committee of Wright State University, Boonshoft 
School of Medicine. Breeder mice lacking a single functional allele of the Slc12a2 gene 
were created by Dr. Gary Shull [Department of Molecular Genetics, Biochemistry and 
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Microbiology, University of Cincinnati (Flagella et al. 1999)] and kindly provided by Dr 
F. J. Alvarez-Leefmans (Department of Pharmacology and Toxicology, Wright State 
University). Mice of the three genotypes, i.e., wild-type (WT), lacking one 
(heterozygous, HE) or two (knock-out, KO) functional alleles of the Slc12a2 gene were 
generated by crossing HE mice breeders with WT mice of the C57BL/6J genetic 
background. All animals were provided with standard chow diet and water ad libitum 
with a 12-h light/dark cycle. Functional tests of glucose homeostasis were performed 
with the help of Dr. Khalid Elased (Department of Pharmacology and Toxicology, 
Wright State University) using mice aged between 21 and 23 days and fasted for 16 hs. 
Body and pancreas weights were recorded for each animal used. Water and food intake 
was determined in preliminary experiments to ensure no differences among genotypes. 
Mice were genotyped by PCR using genomic DNA extracted from the tip of the mouse's 
tail or other tissues post-mortem.  
3.1.4. Cell lines 
         The rat insulinoma β-cell line INS-1E was a kind gift from Dr. Pierre Maechler 
(Université de Genève, Faculté de Médecine). These cells were isolated from parental 
INS-1E based on both their insulin content and their responses to glucose (Merglen, et al. 
2004). INS-1E cells were grown in RPMI medium and equilibrated with 5% CO2 and 95 
% air at 37C°. The medium was supplemented with 10 % fetal albumin serum, 75 µg/ml 
streptomycin and penicillin sulfate. Cells were replated in T-75 flasks (BD Falcon, 
Franklin Lakes, NJ) and stocked after confluence. Functional experiments involving INS-
1E cells were performed in confluent cultures in 6- or 12-well plates. Gene expression 
experiments were performed in confluent cultures growing in T75 flasks. RIN-m5F is 
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other rat insulinoma cell lines were involved in gene expression experiments using the 
same environment of INS-1E as well. The mouse insulinoma β-cell line MIN6 was 
kindly provided by Dr. Jun-Ichi Miyazaky (Department of Nutrition and Physiological 
Chemistry, Osaka University Medical School). MIN6 cells were grown in accordance to 
the original protocol (Miyazaki, et al. 1990). Briefly, MIN6 cells were grown in 
Dulbecco's modified Eagle's medium (DMEM, 25 mM glucose) equilibrated with 5% 
CO2 and 95 % air at 37C°. The medium was supplemented with 10 % fetal albumin 
serum, 75 µg/ml streptomycin and penicillin sulfate. Cells were propagated in T75 flasks 
and stocked after confluence. Functional experiments were performed in confluent cells 
growing in 6- 12 or 24-well plates (BD Falcon, Franklin Lakes, NJ). 
3.2. Methods  
3.2.1. Isolation Islets  
       Mice islets were obtained and cultured following the protocol of Li et al. (Li, et al. 
2009). Briefly, mice were euthanized and their liver/intestines exposed through an 
incision around the upper abdomen. After clamping the duodenum wall to block the bile 
path, pancreas was slowly perfused and distended with 10% FBS-RPMI/antibiotics 
through the common bile duct. Then, pancreas were removed and placed in conical tubes 
containing 2 ml of ice-cold DMEM. After washing two times in ice-cold DMEM (750xg 
5 min), pancreas were transferred to a sterile 10 cm glass Petri dish to be chopped with 
scissors (or surgical blades) into small pieces of ~1 mm3. Then, chopped tissues were 
transferred to new tubes and digested using freshly prepared HBSS (define HBSS)- 3 
mg/ml collagenase XI (1U/µl Sigma, C2014) for 3-5 min at 37.5ºC and vigorous shaking. 
A second round of gentle digestion was allowed for an additional 3-5 min until complete 
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digestion of the tissues. Digestion was stopped by placing the digestion reaction on ice 
and by adding cold 1 mM CaCl2-HBSS. Islets were purified/washed by centrifugation 
(290g, 30s, 4ºC) and resuspension in cold 1mM CaCl2-HBSS. Pure islets were 
immediately processed for protein/RNA purification or plated in 6-well plate containing 
RPMI supplemented with 10 % FBS, 75 µg/m1 streptomycin/penicillin sulfate. Islets 
were allowed to attach by incubated them at 37°C for 3 days in RPMI. Once attached, 
islets were ready for insulin secretion experiments.  
3.2.2. Measurement of blood glucose levels 
        Blood glucose was determined in fasted animals using a Glucometer (FreeStyle-
Lite, Abbott) and a single drop of blood (~3-5 µl) gently obtained from the tip of the 
mice's tails. Briefly, the tail's skin was disinfected with alcohol prior to incising the tip. 
No more than 1 mm of the end of the tail's skin was cut using sharp surgery scissors. This 
procedure was applied to the animal only once and immediately before intraperitoneal 
application of glucose or insulin to obtain basal values of glycaemia and/or insulinemia. 
In the latter case, three to four drops of blood (~20 µl) was collected onto heparinized 
capillary tubes. 
3.2.3. Glucose and Insulin Tolerance tests 
        Glucose homeostasis in mice was evaluated following NIH's recommendations 
(McGuinness, et al. 2009). Basal and post-stimulated glycaemia were determined using a 
glucometer as explained above. Glucose and insulin tolerance tests (GTT) and insulin 
tolerance tests (ITT) were performed by ip administration of 2 g/kg D-glucose or 0.75 
U/kg of human recombinant insulin (HumulinR Eli Lilly & Co. Indianapolis, IN), 
respectively. Glycaemia during GTTs were serially determined by blood sampling from 
 
 
26 
the tip of the tail. Glycemia during ITTs was determined after 0, 20, 30 and 60 minutes of 
insulin injection. 
3.2.4. Sample collection for insulin assay 
         Blood samples were collected onto heparinized capillaries as explained above, 
transferred to 200 µl tubes and immediately centrifuged 4 minutes at 18000xg to collect 
plasma. Plasma samples were stored at −80°C for later use in insulin assay. The 
supernatant of MIN6 or INS-1E cells growing under normal or glucose/drug-stimulated 
conditions was used to determine insulin secretion. Briefly, MIN6 and INS-1E cells were 
plated in 12-well plates at a density of 5×105 cells/well in complete DMEM media 
(Lonza, Cat# 11960-044) supplemented with sodium bicarbonate and 450 mg/dl glucose, 
10 % FBS and 50 µM 2-mercaptoethanol. On day one, cells were washed twice with 
sterile glucose-free Krebs-Ringer Bicarbonate/HEBS buffer [KRBH: 2.7 ml of NaCl 5 M 
(Sigma S5150), 4.8 ml KCl 75 mM (Sigma P9327), 562 µl NaHCO3 0.89M (Sigma 
S8761), 100 µl NaH2PO4 0.5M (Sigma 94046), 50 µl MgCl2 1M (USB 78641), 150 µl 
CaCl2 1 M (Sigma 21114), 1 ml HEPES 1 M (Sigma H0887), 100 mg Bovine albumin 
(Sigma A7906), and deionized H2O to 100 ml]. After washing, cells were incubated for 
30 minutes with 1 ml each well fresh KRBH supplemented with several concentrations of 
glucose to generate a standard curve (Fig. 9). To test drug effects on insulin secretion, 
cells were incubated with KRBH plus several concentrations of the drug. Bumetanide 
stock (10 mM prepared in 0.1% NaOH) was diluted to give a final concentration of 10 
µM, a concentration known to inhibit NKCC1 and NKCC2 (Gamba 2005). Then, glucose 
was added as explained above. After 30 minutes, supernatants were collected, aliquoted 
and stored at −80°C for later determination of insulin concentration. 
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3.2.5. Insulin Assay 
         Insulin concentration in cell culture media and plasma was determined using a 96-
well format ultrasensitive enzyme-linked immunoabsorbent assay (ELISA) from APLCO 
(80-INSMSU-E01). The method is based on a dual-monoclonal antibody sandwich 
format where mouse monoclonal antibodies specific for insulin are immobilized to the 
96‐well microplate as the solid phase and a horseradish peroxidase (HRP) 
enzyme‐labeled monoclonal antibody results in insulin molecules being sandwiched 
between the solid phase and the conjugated antibody.  
 
 
 
 
 
 
 
 
 
 
           Insulin standards, diabetic controls and samples were analyzed in parallel 
following the instructions of the manufacturer. Briefly, samples were incubated on an 
!
 
 
Figure 9: Standard curve for insulin determination. 
Plotted are the results of ten standards curves obtained in 
ten different experiments shown in the sigmoidal 
relationship between the log10 optical density (absorbance 
at 510 nm) and the concentration of insulin (0.025-6.9 
ng/ml). This relationship was used to calculate insulin 
concentration in ng/ml in all our samples from plasma, 
islets, or cell lines.  
 
 
 
28 
orbital microplate shaker at 700-­‐900 rpm for 2 hours. After the first incubation was 
completed, wells were washed and dried. TMB Substrate was added and the microplate 
was incubated a second time on an orbital microplate shaker at 700-­‐900 rpm for 30 
minutes. Once the second incubation period was complete, Stop Solution was added, and 
the optical density (OD) was measured by spectrophotometer at 450 nm with a reference 
wavelength of 620-­‐650 nm. The intensity of the color generated was directly proportional 
to the concentration of insulin in the sample. 
3.2.6. Immunohistochemistry  
         Immunohistochemistry refers to the process of localizing proteins in cells of a tissue 
section by using antibodies. Mice were scarified and then perfused transcardially with ice 
cold PBS to flush out the blood and then with 4 % paraformaldehyde (PFA) for 10 
minutes. Tissues were collected and fixed in 4 % PFA overnight at 4°C. Tissues were 
then sent to AML laboratories (Baltimore, MD) for paraffin embedding and microtomy. 
Paraffin sections were deparaffinized by washing in xylene for 5 min and subsequent 
hydration with 100 %, 95 %, 70 %, 50 % and 30 % ethanol for 5min each. Sections were 
then rinsed with distilled H2O and PBS. Rinsed sections were transferred to water bath 
containing 10 mM sodium citrate and boiled for 30 minutes. Boiled sections were 
blocked using 3 % normal goat/horse/monkey serum (diluted in PBS containing 0.1% 
Triton-X) for 1 hour at 4°C. Primary antibodies NKCC1 (1:500, T4c), NKCC2 (1:500), 
insulin (1:500), and pro-insulin (1:500) were diluted in 3 % normal serum and sections 
were incubated in diluted primary antibodies overnight at 4°C. The sections were then 
washed with 1x PBS three times and incubated with their respective Cy3 and FITC 
secondary antibodies for 2 hours at 4°C. NKCC1 was incubated with donkey anti-mouse 
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secondary antibodies conjugated with FITC. NKCC2 was incubated with goat anti-rabbit 
secondary antibody conjugated with Cy3. Slides were air-dried and mounted using a 
mounting medium containing DAPI (Vectashield, Vector, Burlingame, CA). Images were 
taken using a fluorescence microscope. 
3.2.7. Immunofluorescence 
         Cell lines were grown on cover slips (Fisher Scientific. #NC9130114) placed on 6-
well plates. Cells have cultured in normal media (until ~60-75 % confluence) to provide 
good imaging capabilities. Cells were washed three times with 1X PBS and fixed with 
methanol 10 minutes at −20°C. Cells were permeabilized with 4 % fresh 
paraformaldehyde + 0.25 % Triton X100. Cells plate were washed with 1X PBS three 
times and blocked against non-specific staining using 3% normal goat/horse/monkey 
serum for 1 hour at 4°C. Cells were washed again with 1X PBS and incubated with 
primary antibodies. Primary antibodies NKCC1 (1:500), and NKCC2 (1:500) were 
diluted in 3 % normal serum and cover slips were incubated in diluted primary antibodies 
overnight at 4°C. Next day, slips were washed 3 to 4 times with 1X PBS and blocked 
with their respective Cy3 and FITC secondary antibodies for 2 hours at 4°C. NKCC1 was 
incubated with donkey anti-mouse secondary antibody conjugated with FITC fluorescent 
dye. NKCC2 was incubated with goat anti-rabbit secondary antibody conjugated with 
Cy3 fluorescent dye. Slips were air-dried and placed on slides by flipping them over and 
placed on glass slips for microscopy (24x50mm, 1.5). Vectashield mounting medium 
containing DAPI (Vector, Burlingame, CA) was used to counterstain cell nuclei. Images 
were taken using Olympus FV1000 fluorescence microscope.  
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3.2.8. Morphometric analysis 
        Cell number was computed using NIH ImageJ v1.42G software. Pancreas slides of 
NKCC1 WT and NKCC1 KO mice were cimmunostained using polyclonal antibodies 
against insulin coupled to HRP-conjugated secondary antibodies (DermPrep, Tampa FL).  
Immunostained sections were visualized in a microscope and high-resolution images 
were using oil immersion objectives at 600x magnification. Digital pictures were 
converted to 8 bits and processed in silico. Insulin-positive cells were counted using the 
cell counter plugin of ImageJ and this number was related to the total number of cells in 
the islet. The area of β-cells was calculated from measured diameters in pixels and then 
converted to µm3 assuming β-cells as spheres (volume = 4/3πr3) following described 
procedures (Majid et al. 2001). At least 20 islets per genotype were analyzed.  
3.2.9. Western blot analysis 
         Western blot analysis was performed in protein extracts obtained from tissues or 
cell lines and was based on standard methods (Kurien and Scofield 2009). Briefly, 
confluent cells were washed with 1X PBS three times and collected using scraper (rubber 
policeman). Cells were washed by centrifugation in at 10,000xg for 10 min in phosphate 
buffered saline (PBS) and lysed using lysis buffer containing protease inhibitors 
(Complete LysisTM, Roche Diagnostics, Mannheim, Germany) with the help of a syringe. 
When tissues were used as a source of protein extracts, the following procedure was 
followed: tissues were quickly removed after euthanasia and homogenized on ice in lysis 
buffer containing protease inhibitors. Tissue homogenates were centrifuged at 10,000xg 
for 10 min at 4°C to remove cellular debris. Total protein content was determined in 
supernatant using the Bradford method and BSA as a standard (BioRad, Hercules, CA). 
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Fifty microliters (µl) of tissue lysate was added to 50 µl samples loading buffer (8% SDS, 
125 mmol/L Tris-HCl, pH-6.8, 20% glycerol, 0.02% bromophenol blue, 100 mmol/L 
dithiothreitol) and boiled for 5 minutes. Protein (50-100 µg per lane) was loaded into the 
wells of a 4-20% SDS-PAGE gel and separated by electrophoresis for 1 hour. Proteins on 
gel were then transferred (Bio-Rad transfer apparatus, Hercules, CA) to a 0.2 µm PVDF 
membrane (Millipore, MA). The membrane was blocked for an hour with 10 % non-fat 
milk in 10 mM Tris buffered saline with Tween 20 (TBS-T) at room temperature (RT). 
For analysis of NKCC1, and NKCC2 membranes were probed over night on shaker at 
4°C with mouse anti-NKCC1 (1:250), and rabbit anti-NKCC2 (1:250). Primary 
antibodies were diluted in 5% non-fat milk in TBS-T. The membrane was then washed 
with TBS-T buffer 3 times for 5 minutes at RT. The membrane was then incubated with 
diluted horseradish peroxidase conjugated to donkey anti-rabbit (dilution 1:2000 in TBS-
T), or donkey anti-mouse (dilution 1:2000 in TBS-T) secondary antibodies at RT for 
1hour. The membrane was washed 3 times for 3 minutes using TBS-T buffer. Blots were 
detected using SuperSignal Chemiluminescent substrate and visualized by exposing the 
membrane for a minute using a Fujifilm image analyzer (LAS 3000, image Quant, 
Sunnyvale, CA). The relative amounts of proteins of interest were determined by 
normalizing to β-actin. 
3.2.10. Reverse transcription coupled to the polymerase chain reaction (RT-PCR)  
          Total RNA was obtained from freshly isolated mouse islets, tissues or β-cell lines 
using the RNeasy Protect Mini kit, following the instructions of the manufacturers. Total 
RNAs/cDNAs from tissues were purchased from BioChain (Hayward, CA) or Zyagen 
(San Diego, CA). First-strand cDNA synthesis and PCR was performed as described in 
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detail in our recent publication (Alshahrani and Di Fulvio 2012). Briefly, 2 µg of total 
RNA, 200 ng of random hexamers, 500 mM dNTPs, 10 mM DTT, 40 units RNase OUT 
and 200 units of SuperScript III reverse transcriptase. Reverse transcriptions (RT) 
reactions were incubated at 50ºC for 50 min. After RT, reverse transcriptase was 
inactivated at 85ºC for 5 min. Aliquots of cDNA reaction were amplified using PCR in a 
final volume of 50 µl and the following conditions: 0.5 mM of each dNTP, 1-2 mM 
MgSO4 and 50 pmol of gene-specific primers. The thermal conditions for PCR (iCycler, 
BioRad Hercules CA) were as follows: denaturation at 98ºC for 2 min, followed by 40 
cycles of 30 sec at 95ºC; annealing, 30 sec at 58ºC and extension, 0.5-1 min at 68ºC, 
according to primers and/or predicted amplicon length in bps. The sets of primers used to 
amplify NKCC1, NKCC2 and control transcripts are detailed in Table 1. These primers 
were also used to determine the nucleotide sequence of each RT-PCR fragment produced. 
The nucleotide sequence of RT-PCR fragments was obtained in at least three amplicons 
from separate RT-PCRs using different RNA samples. Sequences of overlapping RT-
PCR fragments were aligned and assembled in silico using and rat/mouse sequences of 
reference (RefSeq) as template models. 
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3.2.11. Quantitative real-time PCR  
         NKCC1 and NKCC2A transcript abundances relative to β-actin mRNAs in β-cells 
were determined using iQ SYBR Green Supermix  (BioRad, Hercules CA) following the 
methodological details recently published (Alshahrani and Di Fulvio 2012) and the 
guidance of Dr. David Cool and Billy Grunwald (Department of Pharmacology and 
Toxicology, Wright State University). Briefly, total RNA from INS-1E β-cells growing 
under basal conditions was used as template. NKCC1, NKCC2A and β-actin mRNAs 
!
 
Table 1. Primer-set sequences and identification. The sense and antisense sequences 
of PCR primers used in this study are shown. PCR primers were designed according to 
mouse, rat or human cDNAs and/or RefSeq nucleotide sequences. PCR primers were 
designed to amplify transcript isoforms (i.e., NKCC1 and NKCC2) and to co-amplify 
splice variants (i.e., NKCC1a, NKCC1b, NKCC2A, NKCCC2B and NKCC2F). 
Primer sets composed by sense (forward) and antisense (reverse) primers are named 
indicating the amplified transcript i.e., NKCC1, NKCC2, GAPDH, followed by 
numbers reflecting the predicted length of the RT-PCR amplicon in base pairs (bp). 
Primer sets were designed using Geneious Pro v5.5 (Biomatters Ltd. Auckland, New 
Zaeland). Some of these primers were designed for other projects in collaboration with 
Dr. Alvarez-Leefmans. 
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were amplified using the following primer sets: NKCC2-150 sense: 5'-TGC TAA TGG 
AGA TGG GAT GC-3', NKCC2-150 antisense: 5'-CAG GAG AGG CGA ATG AAG 
AG-3'; NKCC1-149 sense: 5'-CAC GAT GAG CTG GAA AAG GA-3', NKCC1-149 
antisense: 5'-ATG CAG CGG ACT AAT ACA CC-3'; and β-actin-220 sense: 5'-ACG 
AGG CCC AGA GCA AGA GA-3', β-actin-220 antisense: 5'-GTG TTG AAG GTC 
TCA AAC ATG ATC TGG GT-3'; and the following thermal conditions: initial 
denaturation (hot-start) at 94 ºC 8 min plus 40 cycles at 94 ºC, 65 ºC and 72 ºC 30 sec 
each. Control reactions in the absence of template were included for each primer set. 
Samples were amplified in triplicates. Transcript quantification was based on the ΔCt 
method where Ct is the cycle number at which the amount of amplified target mRNA 
reaches the arbitrary threshold of 0.2 Relative Fluorescent Units above background. 
NKCC1 and NKCC2 mRNA levels relative to β-actin were estimated using the relation: 
target/actin = 2-ΔCt, where ΔCt is the difference between the mean Ct values for the target 
transcript (NKCC1 or NKCC2) and β-actin i.e., ΔCt = CtActin - CtNKCCs. 
3.2.12. DNA sequencing of PCR products  
         All RT-PCR products were sequenced to confirm molecular identity. For sequence 
analysis of PCR products, 10 µl PCR reaction products were purified from single 
stranded DNA and dephosphorylated using a mixture of exonuclease/alkaline 
phosphatase enzymes [ExoSapit (Affimetrix/USB, Cleveland OH)] and incubated in 
programmable thermocycler for 30 minutes at 37C° and 80C° respectively. Purified PCR 
amplicones were sequenced using the same sense and antisense primes used to generate 
the amplicons [Agencourt/Beckman Genomic Services (Beverly, MA)].  
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3.2.13.  In silico analysis  
       DNA sequences, chromatograms, alignments, primer design and annotation of new 
transcript sequences were performed using Geneious software suite v5.5 (Biomatters Ltd. 
NZ www.geneious.com) and several open source algorithms included in the software 
suite such as MAFFT (Katoh, et al. 2002), Clustal W (Thompson, et al. 1994) or Primer3 
(Rozen and Skaletsky 2000). Prediction of trans-membrane domains were performed and 
interpreted using TOPCONS (topcons.cbr.su.se/index.php) as it has been recently 
performed for members of the Slc12a family of genes (Di Fulvio and Alvarez-Leefmans 
2009).   
3.2.14. Statistical analysis  
        Data are expressed as means ± SEM. The trapezoidal method was used to determine 
the area under the curve (AUC) of GTTs and ITTs. The difference between the means of 
two populations was determined using Student’s two-tailed t-test after a preliminary F-
test to determine homogeneity of within-group variances. When more than two groups 
were compared, the differences and significances in glycaemia or insulinemia were 
determined using one-way ANOVA (GraphPad v5, Prism Software, San Diego CA). A 
p<0.05 was used as the criterion for statistical significance. The homeostatic model 
assessment (HOMA), an index of whole body insulin resistance, was calculated from 
fasting plasma insulin concentration in µU/ml (ng/ml × 28.6 = µU/ml) and glycemia in 
mM (mg/dl × 1/18 = mM) using the relationship HOMA = [Insulin] × [Glucose]/22.5. 
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4- RESULTS 
4.1. The Slc12a2 gene impacts insulin release and glucose homeostasis in vivo 
         The results of the next sections i.e., 4.1-4.8 have been submitted for publication 
either in part of in whole. Direct evidence support the notion that the products of the 
Slc12a2 gene i.e., NKCC1 and [Cl–]i are involved in insulin secretion in vivo and in vitro 
[(Best et al. 2010) and references therein]. However, there is no direct evidence of a role 
of NKCC1 insulin secretion. To determine the impact of the Slc12a2 gene in insulin 
secretion in vivo we used mice harboring homozygous (NKCC1 KO) inactivation of this 
gene. Basal plasma levels of insulin and glycaemia were determined in wild type 
(NKCC1 WT) and NKCC1 KO mice in the morning after an overnight period of food 
deprivation (~16 hs). As shown in Figure 10, the lowest plasma insulin concentration is 
found in NKCC1 KO mice. As expected, fasting insulinemia in these mice correlated 
with fasting glycaemia (Fig. 10). However, the HOMA index, a parameter that estimates 
basal β-cell function and insulin sensitivity, calculated for NKCC1 KO was 
approximately ten times lower than that of NKCC1 WT mice (HOMAKO=0.4 and 
HOMAWT=4.3), suggesting that NKCC1 KO is more sensitive to insulin than NKCC1 
WT mice.  
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          To test if NKCC1 KO mice are hypersensitive to insulin, hypoglycemia was 
induced in fasting NKCC1 KO and NKCC1 WT mice by single intraperitoneal injection 
of a standardized dose of human insulin (0.75 U/kg). Glycaemia was monitored during an 
hour post insulin injection. As shown in Figure 11, insulin tolerance tests were not 
significantly different in NKCC1 mice of each genotype, indicating that these mice, 
 
 
 
 
Figure 10: Basal glucose and insulin measurement. A) Glucose measurements test 
(glycaemia test) of NKCC1 WT mice (n=9) and KO mice (n=9) after around 16 hours 
fasting. One-way ANOVA followed by Newman-Keuls Multiple Comparison Test showed 
there was a significant decrease in glucose of KO (62.2 ± 3.0 mg/dl) compared to WT 
(101.2 ± 3.2 mg/dl).  B) Basal insulin levels after 16 hours of food deprivation in NKCC1 
WT and KO mice, n=5 for each group. One-way ANOVA followed by Newman-Keuls 
Multiple Comparison Test showed there was a significant decrease in KO plasma insulin 
(0.10 ± 0.01 ng/ml) vs. plasma insulin in WT (0.68 ± 0.25 ng/ml). *, p<0.0001. Data are 
represented as mean ± SEM. 
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either NKCC1 WT or NKCC1 KO are equally sensitive to exogenously administered 
insulin.  
 
4.2. NKCC1 KO mice exhibit improved insulin secretion 
 Since hypoglycemia 30 minutes post insulin secretion reflects the first phase of 
insulin secretion from β-cells (Gerich 2002a, b) and NKCC1 KO mice are 
hypoinsulinemic relative to NKCC1 WT, our data suggest that NKCC1 KO mice have an 
improved first phase of insulin secretion when compared to NKCC1 WT. To test this 
!
 
 
Figure 11: Insulin-induced hypoglycemia in NKCC1 WT and NKCC1 KO mice. A) 
Shown are blood glucose concentrations obtained at the indicated times post-injection 
of insulin. Every time-point represents glycaemia in mg/dl expressed as the mean ± 
SEM. Time 0 represents time when glucose (2g/kg) was injected intraperitoneally. 
Insulin tolerance tests were performed in fasting NKCC1 WT mice (black circles, 
n=6) and NKCC1 KO mice (red circles, n=6). No statistical differences in glycaemia 
at each time-point were found. B) Maximum hypoglycemic effect of insulin. 
Glycaemia expressed as percentage drop form basal values (mean ± SEM, n=6 in each 
group) 30 minutes post insulin load. No significant difference in insulin-induced 
hypoglycaemia was recorded in these mice. 
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hypothesis, mice of both genotypes were treated intraperitoneally with a single dose of 
glucose and plasma insulin concentration was determined 10 minutes post-injection. As 
shown in Figure 12, plasma insulin levels increased after a load of glucose in these mice 
irrespective of genotype. However, NKCC1 KO mice showed a higher insulin response to 
glucose when compared to NKCC1 WT mice. Therefore, these results suggest that 
NKCC1 KO mice are hypersensitive to glucose by a mechanism related to β-cells and 
thus, challenge the notion that NKCC1 is required for insulin secretion. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
40 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.3. Islets lacking NKCC1 do not have impaired insulin secretion 
 To test the hypothesis that β-cells lacking NKCC1 are hypersensitive to glucose 
and therefore improved insulin secretion in vivo, the secretory response of islets lacking 
NKCC1 was tested in vitro. Islets of the two genotypes i.e., NKCC1 WT and NKCC1 KO 
were incubated under low (2.5 mM) medium (5.5 mM) or high glucose concentrations 
!
 
 
Figure 12: Plasma insulin 
concentrations in NKCC1 WT and 
NKCC1 KO mice. Plasma samples were 
obtained from fasting mice at 0 and 10 
minutes post-intraperitoneal injection of 
glucose. Shown are plasma insulin 
levels in NKCC1 WT (n=6) before (grey 
bar) and 10 min after glucose load 
(black bar) and in NKCC1 KO mice (n= 
6, light red and red bars, respectively). 
One-way ANOVA showed that there is 
a significant increase in the response to 
glucose in NKCC1 KO mice compared 
to NKCC1 WT (*, p<0.001). 
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(20 mM) for 1 hr. As shown in Figure 13, insulin secretion in NKCC1 KO islets shows 
significant increase in glucose-induced insulin secretion comparing with NKCC1 WT 
islets. As predicted by our hypothesis, islets lacking NKCC1 respond to lower 
concentrations of glucose, whereas NKCC1 WT islets do not. Therefore, our results 
demonstrate that Slc12a2 is not necessary for insulin secretion in response to glucose and 
that absence of NKCC1 sensitizes β-cells to glucose. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     
 
Figure 13: Insulin secretion in primary 
cultures of pancreatic islets. Islets obtained 
from NKCC1 WT and NKCC1 KO mice were 
isolated, cultured and exposed to 2.5, 5.5, and 
20 mM glucose for 2 hours. Data represent 
insulin concentration in the culture media 
(mean ± SEM, n=10 for each group) expressed 
as ng/ml (*, p<0.05 one-way ANOVA 
followed by Newman-Keuls Multiple 
Comparison Test). 
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4.4. NKCC1 KO mice exhibit improved glucose tolerance  
 Since the first phase of insulin secretion determines glucose tolerance and 
clearance (Bruttomesso, et al. 1999), NKCC1 WT and NKCC1 KO mice were subjected 
to intraperitoneal glucose tolerance tests (GTT). To this end, fasting mice were injected 
intraperitoneally with a single dose of glucose (2 g/kg) and glycaemia determined at 
several intervals during two hours. As shown in Figure 14, mean glucose levels during 
GTT are lower in NKCC1 KO at critical time-points post glucose injection when 
compared to those of NKCC1 WT mice. These results suggest that NKCC1 KO mice 
have an increased ability to clear the injected glucose by a mechanism related to insulin 
secretion. This is illustrated in the calculated area under each GTT curve (AUC, 
mg/min/dl), a parameter reflecting insulin mobilization and/or sensitivity, and inversely 
proportional to the glucose clearance. As shown in Figure 15, AUC of NKCC1 KO is 
significantly lower than that of NKCC1 WT, suggesting that, contrary to expectations, 
mice lacking both alleles of the Slc12a2 gene have improved glucose tolerance due to 
increased glucose-induced insulin secretion.  
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Figure 14:  Intraperitoneal glucose tolerance tests (GTTs) 
Shown are blood glucose concentrations obtained at the 
indicated times post- injection of glucose. Every time-point 
represents glycaemia in mg/dl expressed as the mean ± SEM. 
Time 0 represents time when glucose (2 g/kg) was administered 
intra-peritoneally. GTTs were performed in fasting NKCC1 WT 
mice (black circles, n=17) and NKCC1 KO mice (red circles, 
n=20) and the statistical differences in glucose concentrations at 
each time-point were calculated using one-way ANOVA 
followed by Newman-Keuls for comparison of multiple 
determinations. Glycaemia was significantly lower in NKCC1 
KO mice relative to NKCC1 WT at all time points (p<0.05). 
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4.5. Homozygous inactivation of the Slc12a2 gene increases β-cell mass  
       The observed changes in glucose homeostasis in NKCC1 KO mice could be 
explained by increased pancreatic β-cell mass. To ascertain this, we analyzed the β-cell 
number within the islets and the number of islets within the pancreas morphometrically in 
sections obtained from NKCC1 WT and NKCC1 KO littermates of 21 days of age and 
immunostained against insulin. As shown in Figures 16 A-B, the number of β-cells/islet 
appears to be higher in NKCC1 KO when compared to NKCC1 WT. To evaluate the 
significance of this observation, insulin-positive cells per islet were counted using the 
!
 
 
Figure 15: Area under the 
curve of GTTs. The areas 
under each glucose tolerance 
test performed in NKCC1 KO 
and NKCC1 WT mice were 
calculated using the 
trapezoidal rule. Results are 
means ± SEM expressed in 
mg/dl of glucose cleared in 
120 minutes for NKCC1 WT 
(n=17) and NKCC1 KO mice 
(n= 20). *, p<0.05, one-way 
ANOVA.  
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NIH's software package ImageJ. As shown in Figure 16 C the number of β-cells was 
increased in NKCC1 KO islets when compared to NKCC1 WT ones. The distribution of 
β-cells (Figure 16 A-B) in NKCC1 KO or NKCC1 WT islets did not change; they were 
the most abundant cells clustered in the core of the islets. Figures 16 D-E show the 
number of islets in pancreas of NKCC1 KO compared to NKCC1 WT mice. Although the 
difference in islet density between NKCC1 WT or NKCC1 KO mice was not significant  
(Figure 16 F), the mean wet weight of NKCC1 KO pancreas was ~50 % lighter when 
compared to NKCC1 WT mice. Similarly, total body weight of NKCC1 WT and NKCC1 
KO mice aging 21-22 days was 11.1 ± 0.4 g (n=44) and 5.4 ± 0.2 g (n=23), respectively. 
Therefore, these results support the hypothesis that NKCC1 KO have higher insulin 
secretory reserve/capacity than NKCC1 WT mice due to an increased number of β-cells 
per islet, a finding consistent with the high insulin response to glucose and the 
consequent high glucose clearance observed in NKCC1 KO mice. 
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Figure 16: β-cell mass in NKCC1 KO mice. A-B) 
Representative insulin immunohistochemistry of 
pancreas obtained from NKCC1 WT and NKCC1 
KO mice. Pictures obtained at high magnification 
to show differences in number and diameter of β-
cells. C) Quantification of the observed β-cell 
number. Results expressed as β-cell number per 
islet (mean ± SEM, *p<0.05). D-E) Same as A-B 
but at low magnification to show differences in 
islet number. F) Quantification of the number of 
islets per µm2 of pancreas tissue. Results expressed 
as mean ± SEM. 
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4.6. Homozygous inactivation of the Slc12a2 gene decreases β-cell volume 
 Since NKCC1 transports water and regulates cell volume (Hamann et al. 2010; 
Hoffmann et al. 2009; Zeuthen and Macaulay 2012) absence of NKCC1 in β-cells 
predicts decreased cell volume. In turn, cell volume changes are known to regulate 
insulin secretion in vitro (Miley, et al. 1998; Miley, et al. 1997). To determine if the 
increased number of β-cells correlated with decreased cell volume, β-cell diameters were 
determined using ImageJ and used to compute β-cell volume assuming them as spheres 
(Majid et al. 2001). As shown in Figure 17, the mean cellular volume calculated for β-
cells lacking NKCC1 was statistically lower that that of WT. Although β-cell shrinkage 
does not explain increased insulin secretion, increased [Cl–]i does. Therefore, our results 
suggest that in the absence of NKCC1, additional mechanisms involved in [Cl–]i are 
present in β-cells to ensure insulin secretion in response to glucose.   
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Figure 17: β-cells volume determination. A-
B) Insulin immunohistochemistry performed in 
pancreas tissues obtained from NKCC1 WT 
and NKCC1 KO mice. C) Soma area of 
insulin-immunostained β-cells in islets was 
calculated from measured diameters in µm. 
Shown are β-cell equatorial diameters 
expressed as mean ± SEM, n>75 *p<0.05. Cell 
volume can be calculated assuming β-cells as 
spheres using the formula vol=3/4πr3, where r 
is half of the cell diameter. 
 
 
49 
4.7. BTD worsens glucose tolerance in NKCC1 KO mice   
            It has been suggested that BTD impairs glucose homeostasis through a direct 
effect on insulin secretion (Furman 1981). However, these were controversial results 
(Giugliano et al. 1980; Hermansen et al. 1985; Robinson et al. 1981). The facts that β-
cells express NKCC1, a protein known to transport Cl– against its electrochemical 
gradient, that insulin secretion in response to glucose is blocked when [Cl–]i in β-cells is 
set at electrochemical equilibrium (Eberhardson et al. 2000; Sehlin 1978) and that β-cells 
lacking NKCC1 are shrunken and hypersensitive to glucose (previous results in this 
Thesis) suggest that β-cells may not require Cl–-dependent pathways to secrete insulin or 
that additional mechanisms are involved in the maintenance of high [Cl–]i in β-cells. To 
examine the latter, we test the role of BTD on glucose homeostasis in NKCC1 WT and 
NKCC1 KO mice. Baseline glycaemia was determined in fasting NKCC1 WT, and 
NKCC1 KO mice 5 mins after a single intraperitoneal low dose of BTD (50 mg/kg). 
Figure 18 shows that an acute dose of BTD significantly increases basal glycaemia in 
NKCC1 WT mice, but it did not have a significant effect in NKCC1 KO mice's fasting 
glycaemia suggesting that β-cells lacking NKCC1 are not acutely sensitive to BTD and 
that basal glycaemia in these mice is kept normal by mechanisms that may not be related 
to basal insulin secretion. However, these results do not exclude the possibility of a 
potential impact of BTD on glucose-stimulated insulin secretion. To test this, we 
examined the impact of BTD on glucose tolerance in NKCC1 WT and NKCC1 KO. 
Fasting NKCC1 KO, and NKCC1 WT mice were subjected to GTTs 5 minutes after 
intraperitoneal injection of BTD. As shown in figure 19, a single dose of BTD did impair 
glucose tolerance in NKCC1 KO and NKCC1 WT mice. Indeed, AUCs of each curve 
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after BTD irrespective of genotype were statistically higher when compared to those 
obtained under normal conditions (Fig. 20). Taken together, these findings suggest that 
BTD impairs insulin secretion in mice deficient in Slc12a2 gene and points toward the 
existence of a BTD-sensitive mechanism involved in the maintenance of high [Cl–]i 
which is different from NKCC1. 
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Figure 18: Effect of BTD on 
basal glycaemia in NKCC1 WT 
and NKCC1 KO mice. NKCC1 
KO (red bars, n=7) and WT 
(black bars, n=7) were treated 
with a single low dose of BTD 
(50 mg/kg) or vehicle (VEH, 
NaOH 0.1 %) five minutes 
before determination of blood 
glucose concentrations. *, 
p<0.05. Data are represented as 
mean ± SEM. 
 
 
 
51 
 
 
 
 
 
 
!
 
 
Figure 19: Glucose tolerance test post BTD treatment. Shown are blood glucose 
concentrations obtained at the indicated times post- injection of glucose. Every 
time-point represents glycaemia in mg/dl expressed as the mean ± SEM. Time −5 
and 0 represents time when BTD (50 mg/kg) or glucose (2 g/kg) was administered 
intra-peritoneally. GTTs were performed in fasting NKCC1 WT mice (black 
circles, n=9) and NKCC1 KO mice (red circles, n=7) and the statistical differences 
in glucose concentrations at each time-point was calculated using one-way 
ANOVA followed by Newman-Keuls for comparison of multiple determinations. 
Glycaemia was significantly lower in NKCC1 KO mice relative to NKCC1 WT 
only in the first 30 minutes of the test (p<0.05). 
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4.8. BTD inhibits insulin secretion in INS-1E β-cells and in islets of NKCC1 KO mice  
         To corroborate the previous results obtained in vivo the inhibitory role of BTD on 
insulin secretion was tested in INS-1E β-cells. As expected, 10 µM BTD, a concentration 
known to inhibit NKCC1 (Gamba 2005; Hoffmann et al. 2009), blocked glucose 
stimulated insulin secretion without impacting basal insulin levels in INS-1E β-cell lines 
!
 
Figure 20:  Area under the 
curves. AUC of glucose 
tolerance test (GTT) for 
NKCC1 WT and KO at 
baseline and after ip injection 
of BTD 50mg/kg. Trapezoidal 
method was used to calculate 
AUC for each GTT curve. 
One-way ANOVA showed a 
significant increase in AUC of 
KO with BTD compared to 
KO before BTD dose. (n=8-9), 
* p<0.05). Data are the mean ± 
SEM of each group. 
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(Fig. 21). To confirm these results, the inhibitory role of BTD on insulin secretion was 
tested in NKCC1 KO islets. As shown in Figure 22, BTD inhibits basal and glucose 
stimulated insulin secretion from primary cultures of islets lacking NKCC1. This 
unexpected result suggests the presence of a BTD-sensitive mechanism involved in basal 
and glucose-stimulated insulin secretion and that this mechanism is not NKCC1. 
Therefore, these results prompted us to search for potential BTD-sensitive Cl– transport 
mechanisms in β-cells at the molecular level. 
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Figure 21: Insulin secretion in INS-1E β-cells. 
Determination of the insulin secretory capacity of 
INS-1E β-cells in response to several concentrations 
of glucose (5.5-20 mM). Cells were cultured until 
confluence in 24-well plates and challenged with BTD 
(10 µM, black bars) or vehicle (blue bars) and the 
indicated concentrations of glucose for 2 h. Insulin 
secreted to the culture media was determined and 
expressed as % increase relative to 5.5 mM.  
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 The next sections i.e., 4.9-4.13 reproduce, with permission of the publisher S. 
Karger AG, Basel, our recent findings published in Cellular Physiology and Biochemistry 
(Alshahrani and Di Fulvio 2012).  
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Figure 22: Insulin secretion from islets lacking NKCC1. 
A) Primary cultures of pancreatic islets obtained from 
NKCC1 KO mice were challenged with two different 
concentrations of glucose: 5.5 mM (100 mg/dl, black bar) 
and 20 mM (360 mg/dl, blue bar). Results are represented 
as insulin concentration in ng/ml of culture media (mean ± 
SEM, *p<0.05). B) Impact of BTD on insulin secretion 
from isolated islets obtained form NKCC1 KO mice. Islets 
were incubated in the presence of BTD (10 µM) or vehicle 
(NaOH 0.1%) for 2 h before challenging islets with 
glucose (5.5-20 mM) for additional two hours. Results are 
expressed as insulin concentration in ng/ml of culture 
media (mean ± SEM, *p<0.05).   
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4.9. β-cells express NKCC1a 
 NKCC1 is expressed in β-cells (Majid et al. 2001). However, it is unknown which 
is the relative contribution of the two known NKCC1 splice variants i.e., NKCC1a and 
NKCC1b to the total NKCC1 pool in β-cells. Therefore, the expression pattern of 
NKCC1 variants was determined in primary cultures of mouse islets, rat and mouse β-
cell lines and different rat and mouse tissues. To this end, we first used the Basic Local 
Alignment Search Tool (BLAST) to screen rat/mouse expressed sequence tags (ESTs) 
posted in the NCBI's EST database (dbEST). As a query, we used mouse sequences 
lacking exon 21 (NKCC1b, Fig. 23 A, top). The database search produced three matches 
from rat tissues: BG666200, BG663902 and BG672434 (Fig. 23 A, center). Therefore, 
rat tissues express NKCC1b and excluding the notion that this variant may not be 
exclusive of the mouse and/or any particular tissue. 
 To confirm this concept, we used specific RT-PCR designed to co-detect 
NKCC1a and NKCC1b mRNA expression in mouse islets, INS-1E β-cells and different 
rat tissues such as kidney, pancreas, stomach, colon and dorsal root ganglia. The latter 
tissue was used as positive control for the co-expression of NKCC1a and NKCC1b (Mao, 
et al. 2012). To this end, we took advantage of the fact that rat and mouse ESTs 
potentially encoding for NKCC1b mRNA lack 48 bp due to alternative exclusion of the 
21st exon (Fig. 23 A) and this difference can be easily detected in PCR reactions designed 
to co-amplify both transcripts. We used an NKCC1-specific set of PCR primers named 
here NKCC1-525a/477b (Fig. 23 B, Table 1) designed to co-amplify in a single RT-PCR 
reaction either rat or mouse NKCC1a and NKCC1b transcripts and to produce two 
amplicons differing in length by 48 bp. As shown in Figure 23 C, RT-PCR products of 
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predicted sizes for NKCC1a transcripts (525 bp) are detected in islets, β-cell lines and rat 
tissues. As expected, transcripts corresponding to NKCC1a and NKCC1b were co-
amplified in dorsal root ganglia. Expression of NKCC1a as the sole Slc12a2 variant in 
islets and β-cell lines was further confirmed by direct sequencing of the purified cDNA 
fragment obtained with the NKCC1-525a/477b primer set in INS-1E β-cells (Fig. 23 D). 
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Figure 23: A) Expression of NKCC1a and NKCC1b mRNA variants was screened in 
dbEST using BLAST and a rat/mouse NKCC1b sequences encompassing exons 20/22 
as a queries. Shown are the three EST clones that matched the queries: BG663902, 
BG666200 and BG672434. To visualize the splicing event, these rat EST clones were 
aligned against rat NKCC1a mRNA sequence of reference (NM_031798). B) Partial 
representation of the mouse NKCC1 gene showing the predicted alternative spliced 
exon 21 that encode for mNKCC1a (NM_009194) or mNKCC1b (predicted). Shown 
are the last ten exons of the gene (filled boxes). Exon numbering is relative to the first 
coding exon of the gene. The exon involved in alternative splicing (exon 21, 48 bp) is 
indicated as a grey box. Introns are represented with V-shaped lines connecting exons. 
White boxes represent the 3'-UTR of the mouse NKCC1 gene. The transcript region 
predicted to be amplified with primer set NKCC1-525a/477b is also shown.  C) RT-
PCR using total RNA from INS-1E, mouse islets (WT) and rat tissues. The NKCC1-
525a/477b primer-set, represented in B, was used to detect and discriminate 
expression of NKCC1a and NKCC1b mRNAs in a single PCR reaction using rat or 
mouse total RNA as template. A band of predicted size (525 bp) corresponding to 
NKCC1a is detected in islets, INS-1E β-cells and in rat tissues tested, whereas two 
bands corresponding to NKCC1a and NKCC1b (577 bp) were detected in total RNA 
obtained from rat dorsal root ganglia (DRG). As negative control for RT-PCR 
reactions, water instead of RNA was used. The primer set used in the control reaction 
was GAPDH-555. D) DNA sequence chromatogram of the band of 525 bp obtained 
by RT-PCR from INS-1E β-cells. Indicated is the region encompassing exons 20, 21 
and 22. Reproduced with permission of the publisher S. Karger AG, Basel. 
 
 
58 
4.10. β-cells express NKCC2A 
 Next, we determined the expression pattern of Slc12a1 gene products in β-cells. 
Expression of NKCC2 transcript variants was analyzed by RT-PCR in transgenic islets 
and in three β-cell lines: INS-1E, RIN-m5F and MIN6. Reverse transcribed total RNA 
from these tissues/cells was PCR-amplified using several species-specific sets of PCR 
primers designed to co-amplify splice variants of NKCC2 i.e., NKCC2A (Slc12a1 variant 
1), NKCC2B (Slc12a1 variant 2) and NKCC2F (Slc12a1 variant 3) (Fig. 24 A, Table 1). 
To amplify Slc12a1 transcripts we used four different primer sets: NKCC2-533, -1010, -
700 and -878 (Fig. 24 A, Table 1). As shown in Figures 24 B-E, mouse islets and β-cell 
lines express NKCC2 at the transcript level. To establish molecular identity of RT-PCR 
amplicons, each PCR product obtained was sequenced in both directions. The partial 
nucleotide sequence of the RT-PCR fragment obtained from INS-1E β-cells (700 bp) is 
shown in Figure 24 F. In silico analysis of this sequence demonstrated ~99 % identity to 
the corresponding region of rat NKCC2A sequence of reference (RefSeq NM_019134, 
Fig. 24 G). Neither exon B nor F at the nucleotide sequence level was found in this 
fragment. The nucleotide sequence of PCR fragments of 533 and 1010 bp also confirmed 
the presence of exon A sequences (not shown).  
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Figure 24: A) Representation of the rat NKCC2A (member 1) mRNA sequence of reference 
(NM_019134). This mRNA is arranged in ~4.6 kb of nucleotide sequence transcribed from 
the rat Slc12a1 gene. The gene contains 32 exons (filled grey arrows), 26 of which encode for 
a protein (NKCC2A NP_062007) including the unique exon A (exon 5, white arrow). Exon 
numbering is relative to the first coding exon. The predicted encoded protein of 1095 amino 
acids is indicated as a black arrow atop the exons of the transcript. Underneath, the predicted 
RT-PCR fragments to be obtained by using NKCC2 primer sets indicated in Table 1. These 
fragments are represented as black arrows labeled NKCC2-533, NKCC2-1010, NKCC2-700 
and NKCC2-878 to indicate that these primer sets are predicted to generate bands of 533, 
1010, 700 and 878 bp, respectively. B-E) Expression of NKCC2 mRNAs in islets of WT mice 
(B), RIN-m5F (C), INS-1E (D) and MIN6 (E) β-cell lines. Reverse transcription coupled to 
PCR of islets or confluent cells' total RNA was performed using the primer sets indicated in 
A. Shown are representative 2 % agarose gels where bands of predicted sizes for NKCC2 are 
detected i.e., 533 bp (WT islets), 1010 bp (RIN-m5F), 700 bp (INS-1E) and 878 bp (MIN6). 
As negative control, RT-PCR reactions were performed using H2O instead of total RNA and a 
primer set designed to amplify transcripts for GAPDH. F) Partial nucleotide sequence of the 
RT-PCR amplicon obtained with NKCC2-700 primer set. The 700 bp RT-PCR product 
amplified from INS-1E cells was purified and sequenced in both directions by PCR using the 
same primers (sense and antisense) used in the original amplification. Shown is a 
representative chromatogram from 6 different amplification reactions. The sequence 
chromatogram corresponds to the region encompassing exons A/B/F of the rNKCC2 
transcripts. G) Alignment of chromatogram's nucleotide sequence against rat NKCC2A 
sequence of reference. Showing is an exact match with exon A (exon 5) of NKCC2A 
(NM_019134). Reproduced with permission of the publisher S. Karger AG, Basel. 
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4.11. Molecular characterization of NKCC2 mRNAs expressed in β-cells 
 To provide convincing evidence of NKCC2A expression as the sole transcript of 
the Slc12a1 gene expressed in β-cells, the complete open-reading frame (ORF) 
containing 3'/5'-UTR sequences of NKCC2A mRNAs were PCR-amplified from INS-1E 
and RIN-m5F cells in overlapping fragments and fully sequenced in both directions. The 
full-length nucleotide sequences of NKCC2A expressed in INS-1E and RIN-m5F β-cell 
lines have been submitted to GenBank under accession numbers JN579707 and 
JN579708, respectively. Shown in Figure 25 is the nucleotide sequence and predicted 
translation product of the Slc12a1 transcript expressed in INS-1E β-cells.   
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         In silico comparison of the predicted translated products of NKCC2A cDNAs 
cloned from rat β-cell lines (JN579707 and JN579708) and rat kidney (BC087017) 
(Strausberg et al. 2002) reveals ~100 % amino acid identity as in figure 26 A. However, 
the full-length nucleotide sequence of rat β-cell NKCC2A cDNAs and NKCC2A cDNAs 
cloned from rat kidney were different in many instances, including the third nucleotide of 
several codons and, in particular, at their 5'-UTRs. As shown in Figure 26 A, alignment 
of NKCC2A 5'-UTRs demonstrates that the rat Slc12a1 gene generates two differentially 
spliced NKCC2A mRNAs. To provide experimental support to this finding and to rule 
!
!
 
Figure 25: Nucleotide and deduced amino acid sequences of NKCC2A expressed in 
β-cells. Shown is the nucleotide sequence of NKCC2A mRNA (3934 bp, GenBank 
JN579707) containing full 5' and 3'-UTRs (nt 1-215 and 3501-4595, respectively) and 
an open reading frame (ORF) of 3285 bp (nt 216-3500) encoding a predicted 1095 
amino acid protein represented with the single letter code.  
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out the possibility of β-cell line-related re-arrangements of the Slc12a1 gene, the genomic 
region encompassing the predicted TSS and the first A1TG of the rat Slc12a1 gene (~1.6 
kb) was PCR-amplified from INS-1E β-cells, sequenced and compared to the relevant 
region of the rat Slc12a1 gene posted in NCBI's map viewer (NC_005102). As illustrated 
in Figure 26 B, sequence analysis of the amplified genomic region demonstrates the 
presence of two non-coding exons: named here exon -2 (22 bp) and exon -1 (64 bp), 
located 10 and 75 bp downstream TSS, respectively. Exon -2 and exon -1 are separated 
by a classic intron of 52 bp (intron -2), whereas an intron of 966 bp (intron -1) separates 
exon -1 from exon 1, the one harboring the first in-frame A1TG codon. Together, our 
results suggest that the Slc12a1 variant 1 (NKCC2A) expressed in β-cells is the result of 
an alternative splicing involving exon -2 and exon 1. 
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Figure 26: A) In silico alignment of the nucleotide sequence of rat NKCC2As corresponding 
to the 5'-untranslated and coding regions. Shown are: the sequence or reference 
(NM_019134), the kidney-derived clone (BC087017) and the two sequences obtained from β-
cells (JN579708 and JN579707). B) Representation of the rat NKCC2A 5'-UTR sequence of 
reference aligned against the kidney-derived rat NKCC2A (BC087017). Shown is the non-
coding exon of 64 bp (exon -1) located immediately up-stream exon 1, responsible for coding 
the last 192 bps of 5'-UTR and the first in frame ATG codon. Also shown is the most distal 
non-coding exon of the rat Slc12a1 gene (22 bp, exon -2) responsible for coding the first 22 
nucleotides of the 5'-UTR. This exon is located 31 bp down-stream a putative transcriptional 
initiation site (TTS, red arrowhead). The sense and antisense PCR primers used to amplify the 
genomic region of the rat NKCC2 gene are indicated as opposite blue arrowheads. The 
alternative splicing of the 5'-UTR region of NKCC2A expressed in INS-1E and RIN-m5F is 
also indicated. Reproduced with permission of the publisher S. Karger AG, Basel. 
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4.12. Expression pattern of NKCC2A transcripts 
 To determine the expression pattern of NKCC2A transcripts containing exon -2/-1 
we performed RT-PCR experiments using exon -2/-1-specific primers and total RNA 
from pancreas, β-cells and different rat tissues where NKCC2 mRNAs have been found 
e.g., kidney and colon (Strausberg et al. 2002; Xue, et al. 2009; Zhu, et al. 2011). To this 
end we used different sets of primers designed to co-amplify NKCC2A mRNAs 
containing exon -1 (NKCC2-920A, -929A and -943A bp, i.e., ~900As bps) or exon -2 
(NKCC2-686) (shown in Fig. 27 A, Table 1). As shown in Figure 26, exon -1 in 
NKCC2A mRNAs is not found in INS-1E β-cells (Fig. 27B), colon (Fig. 27C) or 
pancreas (Fig. 27D), but in kidney (Fig. 27 E), whereas NKCC2 mRNAs containing exon 
-2 (686 bp) were found in these cells/tissues. To confirm molecular identity, the antisense 
strand sequence of RT-PCR fragments from kidney and pancreas was obtained using 
several nested reversed primers. Figure 27 F shows that NKCC2A expressed in pancreas 
lacks exon -1. Hence, our results suggest that the Slc12a1 gene produces at least two 
NKCC2A transcripts in the kidney, which are different in their 5' ends, but only one 
outside the kidney, the one that lacks exon -1. 
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Figure 27: A) Non-scale, partial representation of rat NKCC2A transcripts encoding exon −2 
(white arrow, top) or exon −1 (black arrow, bottom) in their 5'-UTRs. Exons are represented 
as grey arrows and are numbered according to the first coding one. Exon A (exon 5) is 
indicated as a red arrow whereas the coding region of this partial representation is indicated as 
a solid green bar on top of exons. Primer sets used for RT-PCR amplification of NKCC2A 
transcripts differing in 5'-UTRs are indicated. Primer set rNKCC2-686 (exon −2)-specific is 
designed to amplify rat NKCC2 transcripts expressing exon −2 as a single band of 686 bp. 
Primer sets rNKCC2-900As (exon −1 and A)-specific comprise three pairs of primers: 
rNKCC2-920A, -939A and -943A. These primer sets share identical sense primers but three 
different ones specific for rat exon A (exon 5). B-E) Expression pattern of NKCC2A 
transcripts in INS-1E (B), rat colon (C), rat pancreas (D) and rat kidney (E). Bands of 
predicted sizes for NKCC2A transcript expressing exon −2 (686 bp) are detected in these 
rodent tissues whereas mRNAs encoding for exon −1 were only found in kidney. Asterisks 
denote the fragments sequences shown bellow. F) Partial nucleotide sequence of the RT-PCR 
amplicons obtained with NKCC2-689 and NKCC2-943A primer sets. The 689 and 943 bp 
RT-PCR products amplified from pancreas and kidney were purified and sequenced by PCR 
using the antisense primers. Shown is a representative chromatogram from 3 different 
amplification reactions. The sequence chromatogram corresponds to the region encompassing 
exons exon −2, exon −1 and exon 1 of the rNKCC2A transcripts. Reproduced with permission 
of the publisher S. Karger AG, Basel. 
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4.13. NKCC2A, NKCC1a and insulin are co-expressed in β-cells 
 NKCC1 is expressed in β-cells but not in glucagon secreting α-cells (Majid et al. 
2001) where [Cl–]i seems to be below equilibrium (Rorsman, et al. 1989). At the protein 
level, NKCC1 expression was confirmed in INS-1E β-cells, pancreas and mouse islets by 
immunoblotting using a monoclonal antibody directed against the C-terminus of human 
NKCC1. As shown in Figure 28 A, NKCC1a is expressed in these cells and tissues as a 
major band of ~170 kDa, consistent with its N-glycosylated molecular weight (Payne, et 
al. 1995). As expected, NKCC1 expression was not found in islets purified from mice 
deficient in Slc12a2 expression (KO, Fig. 28 A). Taken together, these results suggest 
that only one splice variant of NKCC1 i.e., NKCC1a is expressed in β-cells. 
             To correlate the presence of full-length NKCC2A mRNAs in insulin-secreting β-
cells lines with expression of its predicted product, NKCC2A protein expression was 
determined in β-cell lines and control tissues by immunoblot analysis of total 
cellular/tissue protein extracts using a polyclonal antibody directed against the C-
terminus of rat NKCC2. As shown in Figure 28 B, NKCC2A is detected in β-cells, 
pancreas and islets as two bands, one of ~120 kDa (predicted core MW) and another of 
~160 kDa (N-glycosylated), which is consistent with the known MWs of NKCC2 when 
expressed in the kidney or in oocytes (Ares et al. 2011; Gamba 2005). Notably, NKCC2A 
is detected in mice islets lacking NKCC1 (Fig. 28 B), hence providing evidence that the 
polyclonal antibody used against NKCC2 does not cross-react with endogenous NKCC1. 
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Figure 28: A) Immunoblot analysis of protein extracts 
obtained from INS-1E β-cells, mouse pancreas or transgenic 
islets of the three genotypes i.e., WT, heterozygous (HE) 
and knock-out (KO) probed against NKCC1 using a 
monoclonal antibody directed against the C-terminus of 
human NKCC1. B) Immunoblot of INS-1E, pancreas and 
normal transgenic mouse islets (WT) or lacking one or two 
copies of NKCC1 (HE or KO, respectively). Detected are 
bands corresponding to the core molecular weight of rat 
NKCC2A (~120 kDa) and to its fully N-glycosylated 
version (~170 kDa). Reproduced with permission of the 
publisher S. Karger AG, Basel. 
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 To corroborate that NKCC2A is expressed in insulin-containing β-cells, we 
performed immunofluorescence analysis of fixed pancreas using specific antibodies 
directed against NKCC2 and pro-insulin as a marker of β-cells. Immunostaining of 
pancreas sections obtained from mice lacking NKCC1 revealed the presence of 
immunoreactive NKCC2A as a fine punctate distributed throughout the cytoplasm of 
most but not all cells of the islet (Fig. 29 A, B). There was little if any staining in cells of 
the exocrine secretory pancreas, where NKCC1 is abundantly expressed (Shumaker and 
Soleimani 1999). To provide further evidence of NKCC2A protein expression in β-cells, 
we performed double labeling immunofluorescence experiments in mice islets using a 
monoclonal antibody against pro-insulin and NKCC2. As shown in Figures 29 C-E, 
NKCC2A is detected in cells of the islet that express pro-insulin (β-cells). To extend and 
further confirm co-localization of NKCC1a and NKCC2A in β-cells, co-
immunofluorescence experiments were performed in the rat β-cell line INS-1E. As 
expected, NKCC1a and NKCC2A are co-expressed in these β-cells (Fig. 30).  
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Figure 29:  A-B) Representative indirect immunofluorescence 
of a pancreas slides obtained from NKCC1 WT and NKCC1 
KO mice showing immunoreactivity in most but not all cells of 
pancreatic islets. C-E) Co-immunolocalization of NKCC2A and 
pro-insulin in rat pancreas. Pancreas slides were co-
immunostained using a monoclonal antibody directed against 
pro-insulin (GS-9A8) and anti-NKCC2 antibodies. FITC- and 
Cy3-conjugates secondary antibodies were used to label pro-
insulin and NKCC2A, respectively, whereas nuclei were 
counterstained using DAPI. 
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Figure 30:  A-B) Representative indirect immunofluorescence of 
INS-1E β-cells growing in coverslips. T4 and anti NKCC2 
antibodies coupled to FITC- and Cy3-conjugated secondary 
antibodies were used to label NKCC1 and NKCC2A, 
respectively, whereas nuclei were counterstained using DAPI. 
Shown are NKCC1 (green) and NKCC2 (red) immunoreactivity 
in most of the cell cytoplasm and towards the plasma membrane. 
Results submitted for publication in conjunction with results in 
sections 4.1-4-8 to the Journal of Endocrinology. 
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5- DISCUSSION  
 The "volume regulated anion channel" (VRAC) hypothesis for glucose-induced 
insulin secretion place [Cl–]i above electrochemical equilibrium in β-cells as a key player 
in the first phase of glucose-induced insulin secretion (Best et al. 2010). This hypothesis 
is based on several observations published in the last thirty years or so. Indeed, the first 
recognition that [Cl–]i in β-cells plays a role in insulin secretion was published in 1978 
(Sehlin 1978). Later on, Sehlin's findings were confirmed and extended to many different 
settings (Best 2005; Eberhardson et al. 2000; Kinard and Satin 1995; Lindstrom et al. 
1988; Lindstrom et al. 1986; Somers, et al. 1980; Tamagawa and Henquin 1983). Today, 
ample evidence support the notion that [Cl–]i is maintained above electrochemical 
equilibrium by BTD and furosemide-sensitive NKCC1 (Eberhardson et al. 2000; Majid et 
al. 2001), the only NKCC isoform detected so far in β-cells. A high [Cl–]i makes possible 
the long recognized electrogenic Cl– efflux from β-cells in response to glucose, thus 
contributing to the well-known effect that insulinotropic glucose concentrations have on 
β-cell membrane depolarization and insulin release (Best et al. 2010; Best and Yates 
2010).  
 In spite of those facts, however, we found that mice lacking NKCC1 have 
improved insulin secretion, rather than impaired. Indeed, NKCC1 KO mice had a robust 
insulin response to glucose when compared to NKCC1 WT mice. Further, NKCC1 KO 
mice have improved glucose tolerance than mice harboring intact Slc12a2 genes (Fig. 
14). Since the first phase of insulin secretion determines a better glucose tolerance and 
clearance, our results strongly suggest that the relatively flat glucose tolerance observed 
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in NKCC1 KO mice after a standardized intraperitoneal dose of glucose is due to 
hypersecretion of insulin. This is confirmed in our results of disproportionately increased 
insulin secretion in NKCC1 KO mice 10 minutes post glucose administration (Fig. 12). 
These results were further confirmed by calculating the areas under each GTT curve. 
Indeed, AUCs were significantly decreased in NKCC1 KO compared to NKCC1 WT. 
These findings suggest that NKCC1 KO mice have a better ability to clear glucose than 
that of WT due to increased glucose-stimulated insulin secretion. 
 This surprising finding cannot be easily put in line with the VRAC hypothesis 
considering that our experiments clearly indicate that NKCC1 is neither necessary nor 
sufficient for insulin secretion. Many factors may influence insulin secretion in vivo, 
particularly in NKCC1 KO mice known have significantly less body weight than NKCC1 
WT littermates and present several conditions potentially related to reduced caloric intake 
and salivation impairment in NKCC1 KO mice (Evans, et al. 2000; Flagella et al. 1999). 
It can be argued that this difference is sufficient to promote glucose carving and increase 
tissue sensitivity to insulin, thus offering an explanation on the low plasma levels of 
insulin and low glycaemia observed in NKCC1 KO mice (Fig. 10). However, these 
differences were clearly not feed-related. Indeed, autopsies of NKCC1 KO mice before/at 
weaning time always revealed amounts of milk in their stomachs comparable to NKCC1 
WT littermates. Moreover, after weaning, they feed normally (data not shown). 
Interestingly, at weaning time, some NKCC1 KO mice showed behavioral abnormalities 
such as tremor, food aggression and excitability, particularly after overnight fasting 
period, consistent with symptoms of hypoglycemia.  
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 These in vivo findings may also explain low glycaemia and insulinemia in 
NKCC1 KO mice relative to NKCC1 WT due to increased tissue sensitivity to insulin. 
To determine this, the homeostatic model assessment (HOMA), a parameter to estimate 
the whole body insulin resistance for these mice was calculated. HOMA in NKCC1 KO 
was ten times lower than that of NKCC1 WT mice, suggesting that NKCC1 KO mice are 
either hypersensitive to insulin or their β-cells are hypersensitive to glucose. Should the 
first case hold true, it would be expected that NKCC1 KO mice would reach 
hypoglycaemia faster than NKCC1 WT after a standardized intraperitoneal dose of 
insulin. However, insulin induced hypoglycemia in these mice did not differ among 
genotypes strongly suggesting that NKCC1 KO and NKCC1 WT mice are equally 
sensitive to insulin (Fig. 11). Therefore, increased glucose tolerances in NKCC1 KO 
mice do not appear to be related to increased insulin sensitivity of peripheral tissues to 
insulin, but to increased sensitivity of β-cells to glucose. Our findings regarding low 
basal insulinemia and glycaemia in mice lacking NKCC1 may be related to increased 
sensitivity of β-cells to glucose. Indeed, the same standardized doses of glucose produced 
disproportionate insulin responses in mice lacking NKCC1 relative to WT (Fig. 12).  
            These observations prompted us to investigate the impact of NKCC1 inactivation 
on insulin secretion. NKCC1 KO mice had a robust insulin response to glucose when 
compared to NKCC1 WT mice. It could be argued that the increased insulin secretion 
observed in NKCC1 KO mice is due to the fact that NKCC1 KO mice are hyperkalemic 
(Wall, et al. 2006) and to the known impact that chronic hyperkalemia has on insulin 
secretion (Martinez, et al. 1991). However, islets from NKCC1 KO mice responded 
better to glucose that those obtained from NKCC1 WT (Fig. 13), even at concentrations 
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of glucose known to be non-insulinotropic thus suggesting that islets lacking NKCC1 are 
more sensitive to glucose than those of NKCC1 WT mice.  
 Increased sensitivity of β-cells to glucose can be explained by increased β-cell 
mass (Bouwens and Rooman 2005). Indeed, increased number of β-cells in pancreatic 
islets would result in exaggerated insulin response to glucose when compared to a normal 
β-cell mass. In line, we found that NKCC1 KO mice have increased β-cell mass (Fig. 
16). Although this finding helps to explain increased insulin responses to glucose 
observed in NKCC1 KO mice (Fig. 12), per se it does not explain increased insulin 
secretion neither in vivo nor in vitro without considering [Cl–]i above electrochemical 
equilibrium. Therefore, it appears that in addition to increased β-cell number an increased 
[Cl–]i is necessary to support the notion that β-cells lacking NKCC1 are hypersensitive to 
glucose. It has been demonstrated that membrane ion channels and transporters are 
important for cell proliferation (Hoffmann 2011; Ohsawa, et al. 2010; Panet, et al. 2002; 
Panet, et al. 2000; Stutzin and Hoffmann 2006). For instance, Cl– channels play a key 
role in S phase progression of the cell cycle (Ohsawa et al. 2010). Further, NKCC1 
promotes cell proliferation, mitogenic stimulation and transformation and its inhibition 
with BTD or furosemide reduces cell proliferation (Panet et al. 2002; Panet et al. 2000). 
Mechanistically, NKCC1 indirectly provokes activation of ERK/MAPK signal 
transduction pathways controlling cell proliferation (Panet et al. 2002). The link between 
NKCC1 and cell proliferation may be related to [Cl–]i above equilibrium or to the fact 
that L-type Ca2+ channels abundantly expressed in β-cells are known to be indirectly 
sensitive to a drop in [Cl–]i (Babai, et al. 2010; Henquin 1998; Jakab, et al. 2006). In turn, 
[Ca2+]i is necessary for β-cells proliferation (Nguidjoe, et al. 2011). Therefore, either 
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persistently high [Cl–]i or [Ca2+]i are predicted to impact β-cells proliferation. In line, it 
has been recently reported that [Cl–]i above equilibrium is required for G1-to-S 
progression of the cell cycle (Ohsawa et al. 2010) and chronically high [Ca2+]i increases 
β-cells mass (Nguidjoe et al. 2011). Therefore, high [Cl–]i and [Ca2+]i in β-cells lacking 
NKCC1 may explain our findings. However, a high [Cl–]i in β-cells lacking NKCC1 
requires a transporter with the potential to upload Cl– against its electrochemical 
equilibrium. 
 In the absence of NKCC1, other genes may potentially be involved in the 
regulation of [Cl–]i in β-cells. These cells express some anion exchangers of the family 
Slc4a, Slc26a and Slc9a known to exchange Cl– and HCO3– (AEs) or Na+ and H+ (NHEs) 
(Best, et al. 1996; Miley et al. 1998; Miley et al. 1997). However, the most abundant 
member of the Slc9a gene family expressed in islets i.e., NHE1 has little or no role on 
glucose-induced insulin secretion (Stiernet, et al. 2007). On the contrary, the widely 
expressed disulfonic stilbene (DIDS)-sensitive Cl−/HCO3− exchanger-2 (AE2) may be 
involved in [Cl–]i regulation in β-cells. In fact a DIDS-sensitive Cl−/HCO3− exchanger of 
unknown molecular identity was proposed to be involved in transient insulin secretion 
under hypotonic conditions (Best et al. 1996). Additional potential candidates implicated 
in [Cl–]i regulation in β-cells may be the products of the Slc12a1 and Slc12a3 genes. 
Interestingly, hydrochlorothiazide, an inhibitor of the Slc12a3 gene product NCC, 
inhibits insulin secretion from cultured islets. However, this effect was not related to the 
known ability of NCCs to regulate [Cl–]i (Sandstrom 1993). It is worth mentioning that 
we did not find convincing molecular evidence of NCC transcripts expressed in rat β-
cells lines (data not shown). Although our results do not exclude the possibility of very 
 
 
76 
low levels of the transcript or its protein, it remains to be established if the observed 
effect of hydrochlorothiazide on insulin secretion is due to mechanisms dependent or 
independent of NCC in β-cells. 
 Based on the known facts that BTD inhibits insulin secretion in vitro and in vivo 
(Sandstrom 1988, 1990), that [Cl–]i at equilibrium blunts β-cell response to glucose 
(Lindstrom et al. 1988; Lindstrom et al. 1986; Sehlin 1978) and that BTD had 
controversial effects on glucose tolerance in man and other mammals (Furman 1981; 
Giugliano et al. 1980; Hermansen et al. 1985; Robinson et al. 1981) we reasoned that the 
variability in BTD outcomes may be related to expression variability of genes involved in 
Cl– handling. To test this possibility, we first studied the effect of BTD on glucose 
tolerance in mice lacking NKCC1. To our surprise, we found that BTD does impair 
glucose tolerance in NKCC1 KO mice as well as in NKCC1 WT without impacting basal 
glycaemia in the former. Although the effect of BTD on NKCC1 KO mice glucose 
tolerance may be a consequence of mechanisms not related to insulin secretion, we found 
that BTD also blocked insulin secretion from islets lacking NKCC1 (Fig. 22) as well as in 
β-cell lines (Fig. 21) therefore indicating that BTD may impair glucose tolerance in mice 
lacking NKCC1 by a direct effect on β-cells.  
 This new hypothesis required the presence of a BTD-sensitive Cl– transport 
mechanism in β-cells, which in turn must be functional in β-cells lacking NKCC1. At 
least to non-exclusive possibilities explain our results: i) β-cells of NKCC1 KO mice 
express a new NKCC1 variant where the targeted exon 6 of the gene is spliced out 
generating a BTD-sensitive NKCC1 variant with the potential to regulate [Cl–]i and ii) 
NKCC2 is expressed in β-cells. To test the first hypothesis, we screened gene expression 
 
 
77 
of all potential transcripts produced by the Slc12a2 gene in β-cells lines, islets and 
tissues, including those from NKCC1 KO mice. Using RT-PCR, NKCC1 mRNA 
expression was confirmed in β-cells and islets and its molecular identity established as 
NKCC1a (Fig. 23). We did not find evidence of NKCC1b expression in β-cells and other 
tissues such as pancreas, kidney, colon or stomach (Fig. 23C). These were expected 
findings based on the current notion that NKCC1a, not NKCC1b is the most abundantly 
expressed variant in polarized epithelia (Carmosino, et al. 2008). Further, we found both 
NKCC1a and NKCC1b transcripts in neurons of dorsal root ganglia, in agreement with 
recent work (Mao et al. 2012). Therefore, the possibility that undetectable levels of 
NKCC1b in β-cells are the result of inappropriate primer design is minimized. 
 To test the second hypothesis, the one stating that NKCC2 is expressed in β-cells, 
we followed a similar approach as for NKCC1. This study clearly demonstrated that 
NKCC2 is expressed in insulin-secreting β-cells (Fig. 24 B). Although this unexpected 
finding argues against the long-standing paradigm that NKCC2 mRNAs and proteins are 
exclusive of the tubular cells (Ares et al. 2011; Gamba 2005; Gamba et al. 1994), it has 
become clear that NKCC2 is expressed outside the kidney. Molecular, immunological 
and/or functional evidence of NKCC2 expression has been found in several kinds of 
neurons or interneurons such as the ones of mesenteric ganglia, enteric secretomotor or 
starburst amacrine (Gavrikov et al. 2006; Xue et al. 2009), and in cells of the gastric, 
intestinal, endolymphatic sac and olfactory epithelia (Akiyama et al. 2010; Akiyama et al. 
2007; Ji, et al. 2012; Kakigi et al. 2009; Nickell et al. 2007; Nishimura et al. 2009; Xue et 
al. 2009; Zhu et al. 2011). In fact, it is apparent that NKCC2 is present widely among 
tissues, although at lower levels when compared to kidney [reviewed in detail in (Di 
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Fulvio and Alvarez-Leefmans 2009)]. In line, real time quantitative PCR experiments 
demonstrated low levels of NKCC2 transcripts in β-cells; almost 10 times less abundant 
than those for NKCC1a (Alshahrani and Di Fulvio 2012). These results raise the 
possibility that NKCC2 may play a secondary/less prominent role in total cellular NKCC 
transport. However, protein data does not support this notion. In spite of the fact that 
NKCC2 transcripts were less abundant than NKCC1 mRNAs, at the protein level such 
relationship was not conserved suggesting that NKCC2 mRNAs may be efficiently 
translated into protein in β-cells. 
         The relatively abundant NKCC2 protein expressed in β-cells may be result of 
mRNAs with specific features, particularly at their 5'- or 3'-untranslated regions (UTR). 
To gain insights into the molecular identity of NKCC2 transcripts, we amplified and 
sequence the full-length NKCC2 mRNA expressed in two different β-cell lines (Figure 
25). The results clearly demonstrate that it is the Slc12a1 variant 1 (NKCC2A) the 
NKCC2 spliced version expressed in β-cells and outside the kidney (Figs. 24) 
(Alshahrani and Di Fulvio 2012). We did not find evidence of other members of the 
NKCC2 family, namely NKCC2B or NKCC2F. In silico analysis of full-length rNKCC2 
cDNAs cloned from two different β-cell lines demonstrated the presence of an open 
reading frame (ORF) predicted to encode a protein of 1096 amino acids 100 % identical 
to NKCC2A protein translated from a cDNA cloned from rat kidney (BC087017) and the 
rat NKCC2A protein sequence of reference (NP_062007). However, the nucleotide 
sequence corresponding to the 5'-UTR region of β-cell's NKCC2A was different from 
BC087017 and from the rat NKCC2A mRNA sequence of reference posted in RefSeq 
database (NM_019134). Indeed, an alternative splicing event was evident in NKCC2A 5'-
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UTR. We found two short non-coding exons (i.e., exon −2 and exon −1) located 
downstream from the putative TATA box and up-stream from the first coding exon of the 
rat Slc12a1 gene. Hence, we provide for the first time evidence that NKCC2A mRNAs 
expressed in β-cells or outside the kidney are the result of alternative splicing involving 
exon −2 and the first coding exon 1 of the slc12a1 gene (Alshahrani and Di Fulvio 2012). 
Although the differences in NKCC2A 5'-UTRs are due to a variation between an 
NKCC2A mRNAs expressed in the kidney and non renal tissues, we did not find 
evidence of exon −2 expression in the form of ESTs from many species (data not shown). 
However, the nucleotide sequence of the first cloned full-length rat Slc12a1 (variant 3, 
NKCC2F, U10096) does contain exon −2/exon 1 splicing, thus demonstrating that the rat 
Slc12a1 gene can express exon −2 in the rat kidney, at least as part of variants 1 and 3. 
Exon −1, however, was found in a single EST from rat kidney (CK483746) and in a full-
length NKCC2A cDNA (BC087017) (Strausberg et al. 2002). 
 These results demonstrate that two NKCC2A transcripts can be found in rat 
tissues that are different in their 5' ends: one encoding exon −2 in the kidney and extra-
renal tissues, and another encoding exon −1 in the rat kidney only (Alshahrani and Di 
Fulvio 2012). The existence of two NKCC2A mRNAs encoding for one protein in rat 
kidney tissues suggests that either different TTSs and/or core promoter elements are 
functionally present in the rat Slc12a1 gene, as bioinformatic analysis of Slc12a1 genes, 
which have been already predicted (Di Fulvio and Alvarez-Leefmans 2009). The 
difference in 5'-UTRs may impact NKCC2A expression levels outside the kidney, either 
in a developmental stage-specific and/or temporal manner, and/or the stability of the 
mRNAs and/or efficiency of its translation. Additional experiments are needed to 
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determine if different 5'-UTR NKCC2A variants are the result of activation of different 
promoters acting and/or regulated in a tissue-restricted manner. 
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6- COUNCLUSION   
 β-cells keep [Cl–]i higher than equilibrium (Eberhardson et al. 2000), which in 
turn plays an important role in plasma membrane depolarization and insulin secretion 
(Best et al. 2010; Henquin et al. 2009). NKCC1 has been proposed as the co-transporter 
involved in regulation of [Cl–]i in β-cells and thus considered an important player in 
insulin secretion (Best 2005). Our study suggests that insulin secretion in response to 
glucose is conserved if not improved in mice lacking NKCC1 and that BTD-sensitive 
mechanisms different from NKCC1 are involved in insulin secretion (results submitted). 
We have found that NKCC2A is expressed in β-cells and that this co-transporter, 
NKCC1, and pro-insulin are co-expressed in the same cells (Alshahrani and Di Fulvio 
2012). Therefore, our results provide evidence supporting the new concept that NKCC2 
may contribute to the control of the ion environment within β-cells, particularly [Cl–]i and 
therefore NKCC2 may be involved in insulin secretion. Although the exact mechanisms 
whereby [Cl–]i regulates insulin secretion in response to glucose remain to be determined, 
the electrogenic efflux of Cl– from β-cells enabled by the action of NKCCs contributes to 
glucose-induced membrane depolarization and therefore insulin secretion.
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APPENDIX A 
NKCC1 expression regulation by loop-diuretics 
 
Saeed Alshahrani & Mauricio Di Fulvio. 
 
Department of Pharmacology and Toxicology, Boonshoft School of Medicine, Wright 
State University, Dayton, OH 
Na+K+2Cl– co-transporters are secondary active transport proteins involved in cell 
volume regulation and in the maintenance of the intracellular chloride concentration ([Cl–
]i) at levels above electrochemical equilibrium. Two different genes (Slc12a1 and 
Slc12a2) encode for two isoforms of the transporter, named NKCC1 and NKCC2. 
NKCC1 is a ubiquitously distributed protein whereas NKCC2 is expressed exclusively in 
the apical membrane of the thick ascending portion of the Henle's loop where it plays a 
key role in NaCl and water absorption. NKCC transport activity is inhibited by loop-
diuretics such as bumetanide and furosemide, drugs that are used for the treatment of 
edema associated with congestive heart failure. In spite of the very well known 
pharmacological effects of loop-diuretics of NKCC function, relatively nothing is known 
regarding the impact of these drugs on NKCC1 gene expression. We screened several cell 
lines suitable for gene expression studies and found that COS-7, a kidney fibroblast-like 
cell line expresses NKCC1 at the functional and molecular levels. NKCC1 expression 
was ascertained by Western bolt, immunofluorescence and reverse transcription (RT) 
coupled to the polymerase chain reaction (PCR). Our results show that NKCC1 is 
expressed as a protein of ~170 kDa. Under basal conditions NKCC1 is mainly localized 
in the perinuclear region as well as in small intracellular compartments whereas a small 
fraction is localized near or at the plasma membrane. Upon chronic treatment with loop-
diuretics, COS-7 cells shrunk, as expected. This finding correlated with down regulation 
of NKCC1 protein expression and re-localization/retention/concentration of NKCC1 in 
the perinuclear region in structures resembling the Golgi apparatus. We conclude that 
loop-diuretics regulate NKCC1 protein expression and localization in COS-7 cells. 
Poster presented in Ohio Physiological Society (OPS), 2011, University of Cincinnati, 
Cincinnati, OH. 
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APPENDIX B 
 
Short-hairpin RNA-mediated silencing of NKCC1 in COS7 cells and its effect on cell 
volume 
 
Saeed Alshahrani & Mauricio Di Fulvio. 
 
Department of Pharmacology and Toxicology, Boonshoft School of Medicine, Wright 
State University, Dayton, OH 
 
Na+K+2Cl– cotransporters (NKCCs) effect the electroneutral movement of Na+, K+ and 
2Cl– ions across the plasma membrane. Under physiological conditions NKCCs function 
as active, Na+-dependent, Cl– uptake transporters. Two NKCC isoforms, encoded by two 
different genes have been identified: NKCC1 and NKCC2. NKCC1 is a ubiquitously 
expressed gene whereas NKCC2 is considered to be exclusive of the kidney. We describe 
for the first time a viable knock-down strategy to silence endogenous NKCC1 expression 
in a widely used, easy to transfect cell line. NKCC1 mRNA expression in COS7 cells 
was eliminated transfecting these cells with a poly-cistronic vector encoding for GFP and 
an shRNA directed against the third exon of human NKCC1. Stable transfectants were 
selected by continuous incubation in the presence of puromycin. Cells stably expressing 
GFP and resistant to the drug were selected and cloned. NKCC1 expression was followed 
by Western bolt, immunofluorescence and reverse transcription (RT) coupled to the 
polymerase chain reaction (PCR). The impact of NKCC1 depletion on cell volume was 
followed morphometrically. We found that cells lacking NKCC1 are shrunken suggesting 
that NKCC1 is the sole regulator of cell volume in these cells. This new cell system will 
open the possibility to study the functional, pharmacological and molecular properties of 
candidate genes involved in volume regulation. 
 
 
Poster presented at the Experimental Biology (EB) meeting 2012; San Diego, CA. 
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APPENDIX C 
 
Insulin secretion in mice deficient in the Slc12a2 gene 
 
Saeed Alshahrani & Mauricio Di Fulvio. 
 
Department of Pharmacology and Toxicology, Boonshoft School of Medicine, Wright 
State University, Dayton, OH 
Insulin secretion from pancreatic β-cells is a complex process involving the integration 
and interaction of multiple external and internal stimuli. The most well known 
mechanism whereby glucose induces insulin secretion involves the ATP-dependent K+-
channel pathway. Glucose metabolism within the β-cell increases the ATP/ADP ratio 
closing K+-channels and thus depolarizing the plasma membrane. This activates voltage-
dependent Ca2+-channels inducing Ca2+ influx and triggering insulin secretion from 
stored granules. However, in addition to this cationic pathway, glucose also stimulates 
Cl– efflux. This contributes to β-cell's electrical and secretory activities. The electrogenic 
efflux of Cl– in response to glucose is possible because β-cells maintain the intracellular 
chloride concentration ([Cl–]i) above electrochemical equilibrium due to the functional 
presence in these cells of the Na+K+2Cl– co-transporter, a protein encoded by the Slc12a2 
gene. This co-transporter is the target of loop-diuretics such as bumetanide or furosemide. 
Accordingly, these drugs are known to impair insulin secretion in response to glucose. 
However, our results show that glucose-induced insulin secretion is far from being 
impaired in mice carrying heterozygous or homozygous inactivation of the Slc12a2 gene. 
Transgenic mice lacking one or both functional alleles of this gene have better fasting 
glycaemia and improved glucose tolerance when compared to WT. Further, mice 
deficient in the Slc12a2 gene are more sensitive to glucose when compared to WT 
littermates whereas overall insulin sensitivity is maintained in these mice, regardless of 
genotype. Together, or results suggest for the first time that i) the Slc12a2 gene is not 
required for glucose-induced insulin secretion, ii) additional mechanisms are involved in 
regulating [Cl–]i in β-cells and, iii) hemiexpression of the Slc12a2 gene in these mice may 
have a positive impact in glucose homeostasis. 
 
 
Poster accepted for presentation at the Endocrine Society's Annual Meeting 2012 
(ENDO2012); Houston, TX. 
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APPENDIX D 
 
Rattus norvegicus cell-line INS-1E solute carrier family 12 
member 1 (Slc12a1) mRNA, complete cds 
GenBank: JN579707.1 
LOCUS    JN579707                4595 bp    mRNA    linear   
ROD 06-NOV-2011 
DEFINITION Rattus norvegicus cell-line INS-1E solute carrier 
family 12 member 1 (Slc12a1) mRNA, complete cds. 
ACCESSION   JN579707 
VERSION     JN579707.1  GI:354992502 
KEYWORDS 
SOURCE      Rattus norvegicus (Norway rat) 
  ORGANISM  Rattus norvegicus 
   Eukaryota; Metazoa; Chordata; Craniata;   
   Vertebrata; Euteleostomi; Mammalia; Eutheria;  
   Euarchontoglires; Glires; Rodentia; 
   Sciurognathi; Muroidea; Muridae; Murinae;   
   Rattus. 
REFERENCE   1  (bases 1 to 4595) 
  AUTHORS   Alshahrani,S. and Di Fulvio,M. 
  TITLE     Expression of the slc12a1 gene in pancreatic  
   ß-cells: Molecular characterization and in  
   silico analysis. 
  JOURNAL   Cell Physiol Biochem 30:95-112 
REFERENCE   2  (bases 1 to 4595) 
  AUTHORS   Alshahrani,S. and Di Fulvio,M. 
  TITLE     Direct Submission 
  JOURNAL   Submitted (12-AUG-2011) Pharmacology & 
Toxicology, Wright State 
            University - BSOM, 3640 Colonel Glenn Hwy 216 
Health Sciences Bldg, 
            Dayton, OH 45435, USA 
FEATURES             Location/Qualifiers 
     source          1..4595 
                     /organism="Rattus norvegicus" 
                     /mol_type="mRNA" 
                     /db_xref="taxon:10116" 
                     /cell_line="INS-1E" 
     gene            1..4595 
                     /gene="Slc12a1" 
                     /gene_synonym="Nkcc2" 
     CDS             216..3503 
                     /gene="Slc12a1" 
                     /gene_synonym="Nkcc2" 
                     /note="Na/K/2Cl co-transporter variant 2 isoform A; 
                     rNKCC2A" 
                     /codon_start=1 
                     /product="solute carrier family 12 member 1" 
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                     /protein_id="AER46075.1" 
                     /db_xref="GI:354992503" 
                     /translation="MSVNIPSNSVPSGASRFQVHVINEGHGSGAAMSDSTDPPHYEET 
                     SFGDEAQNRLKISFRPGNQECYENFLQTGETAKTDTTFHAYDSHTNTYYLQTFGHNTM 
                     DAVPKIEYYRNTGSVSGPKVNRPSLQEIHEQLAKNVAVAPGSADRVANGDGMPGDEQT 
                     ENKEEDVTGVVKFGWVKGVLVRCMLNIWGVMLFIRLSWIVGEAGIGLGVLIILLSTMV 
                     TSITGLSTSAIATNGFVRGGGAYYLISRSLGPEFGGSIGLIFAFANAVAVAMYVVGFA 
                     ETVVDLLKESDSMMVDPTNDIRIIGSITVVILLGISVAGMEWEAKAQVILLVILLIAI 
                     ANFFIGTVIPSNNEKKSRGFFNYQASIFAENFGPRFTKGEGFFSVFAIFFPAATGILA 
                     GANISGDLEDPQDAIPRGTMLAIFITTVAYIGVAICVAACVVRDATGSMNDTVVSGMN 
                     CNGSAACGLGYDFSRCQHEPCQYGLMNNFQVMSMVSGFGPLITAGIFSATLSSALASL 
                     VSAPKVFQALCKDNIFKGLQFFAKGYGKNNEPLRGYFLTFVIAMAFILIAELNVIAPI 
                     ISNFFLASYALINFSCFHASYAKSPGWRPAYGIYNMWVSLFGAILCCAVMFVINWWAA 
                     VITYVIELFLYIYVTYKKPDVNWGSSTQALSYVSALDNALELTTVEDHVKNFRPQCIV 
                     LTGGPMTRPALLDITHAFTKNSGLCICCEVFVGPRKLCVKEMNSGMAKKQAWLMKNKI 
                     KAFYAAVAADCFRDGVRSLLQASGLGRMKPNTLVIGYKKNWRKAPLSELENYVGIIHD 
                     AFDFEIGVVIVRISQGFDISPVLQVQDELEKLEQERLALEAAIKDNDCEEGKGGIRGL 
                     FKKAGKLNITKPAPKKDSNISTIQSMHVGEFNQKLVEASAQFKKKQGKGTIDVWWLFD 
                     DGGLTLLIPYILTLRKKWKDCKLRIYVGGKINRIEEEKISMASLLSKFRIKFADIHII 
                     GDINIKPNKESWKVFEEMIEPYRLHESHKDLTTAEKLKRESPWKITDAELEAVKEKSY 
                     RQVRLNELLQEHSRAANLIVLSLPVARKGSISDLLYMAWLEILTKNLPPVLLVRGNHK 
                     NVLTFYS" 
ORIGIN       
     1 cagaaggcgg ctgaatggga ggcagctttg ggaatcattc tgaagattac atgggagacc 
       61 acatatcaac attacagcag gaatccagct atcgggtcgt ctagatccaa aaccaagtgc 
      121 tcggtattgt aaccctacga ttctctattt tgaagcagaa gtaggttaaa acaccaacca 
      181 ctgtaaaata ggtagttcaa agtagatttt ggaagatgtc agtcaacatc ccttccaact 
      241 cagtgcccag tggtgccagt cgtttccaag tccatgttat aaatgagggc catggcagtg 
      301 gtgcagccat gagtgacagc acggaccccc cacattatga agagacctct ttcggggatg 
      361 aagcccaaaa cagactgaaa atcagcttta ggcctgggaa tcaggagtgc tatgaaaatt 
      421 ttctccaaac tggagagact gctaaaacag acaccacgtt tcacgcctat gactctcaca 
      481 caaacacata ttacctacaa acctttggcc acaacaccat ggacgccgtc cccaagattg 
      541 agtactaccg caacaccggc agtgtgagcg ggcccaaggt caaccggccg agcctgcagg 
      601 agatccacga gcagctagct aagaatgtgg ctgtggctcc tggttcagct gacagggttg 
      661 ctaatggaga tgggatgcct ggagatgagc aaacagaaaa caaggaagaa gacgtgactg 
      721 gtgttgtgaa gtttggatgg gtgaaaggtg tgctggtgag gtgcatgctg aacatctggg 
      781 gagtcatgct cttcattcgc ctctcctgga ttgtaggaga agcgggaatt ggtcttggag 
      841 ttctcataat tcttctttcc accatggtaa cttctattac tgggttgtca acttctgcga 
      901 tagcaactaa cgggtttgtt cgtggaggtg gggcctacta tcttatttcc agaagtttag 
      961 ggcccgagtt cggtgggtca ataggcctga tctttgcttt tgctaatgca gtggctgttg 
     1021 ctatgtatgt ggtgggattt gctgagactg tagtagatct tcttaaggag agtgattcga 
     1081 tgatggtgga tccaaccaat gacatccgga ttataggctc catcacagtg gtgattcttc 
     1141 taggaatttc agtagctgga atggaatggg aggcaaaggc ccaagtcatt cttctggtca 
     1201 ttcttctaat tgctattgca aacttcttca ttggaactgt cattccatcc aacaatgaga 
     1261 aaaagtccag aggtttcttt aattaccaag catcaatatt tgcagaaaac tttgggccac 
     1321 gcttcacaaa gggtgaaggc ttcttctctg tctttgccat ttttttccca gcagctactg 
     1381 ggattcttgc tggtgccaat atctcaggag atttggagga tccccaagat gccatcccca 
     1441 gagggaccat gctggccatt ttcatcacca ccgtcgccta cataggtgtt gctatttgcg 
     1501 tagctgcctg tgtggtccga gacgccactg ggagcatgaa cgacactgtc gtttctggga 
     1561 tgaattgcaa tgggtccgca gcctgcggac tgggctacga cttctcaaga tgtcagcatg 
     1621 agccatgcca gtatgggttg atgaacaatt ttcaggtcat gagcatggtg tccgggttcg 
     1681 gccccctcat caccgcaggg atcttttcgg caacactgtc ttcggcccta gcctccctcg 
     1741 tcagtgcacc caaagtattc caggctctgt gcaaggacaa catcttcaaa ggacttcagt 
     1801 tcttcgcaaa gggctatggg aaaaacaacg agcccctgag agggtacttc ctcacttttg 
     1861 tgatagccat ggcattcatt ctcatcgccg agctgaacgt cattgcacct atcatatcca 
     1921 acttcttcct ggcctcatat gcgcttatta atttctcctg cttccatgcc tcgtatgcca 
     1981 aatcgccagg atggaggccg gcatatggga tttacaacat gtgggtatct ctcttcggag 
     2041 ccattttgtg ctgtgcagtc atgtttgtca tcaactggtg ggcggctgtc atcacctatg 
     2101 tcattgagct cttcctctat atctatgtga cttataagaa gccagatgtg aactggggct 
     2161 cctccacaca ggctctgtcc tacgtgagcg ctttagacaa tgctctggaa ttaaccacag 
     2221 tggaagacca tgtgaaaaac ttcagacccc agtgcattgt cttaacagga ggacccatga 
     2281 caagacctgc tctcctggac ataacccatg cctttacgaa gaatagtggc ctctgtatct 
     2341 gctgcgaagt cttcgtggga cctcgcaagt tgtgtgttaa agagatgaac agtggcatgg 
     2401 ctaaaaagca ggcctggctg atgaagaaca aaatcaaggc tttttatgct gcggtggcgg 
     2461 cagactgctt cagggacggt gtgcggagtc tccttcaggc ctcaggcctg gggagaatga 
     2521 agccaaacac tctagtgatt ggatacaaaa agaactggag gaaagctccc ttgtctgagc 
     2581 ttgagaatta cgtgggaatc atacatgacg cctttgactt tgagattggt gtagtcatag 
     2641 tcagaatcag ccaagggttt gacatctctc cagttctcca ggtacaagat gaactggaga 
     2701 aactggaaca ggagagactg gctctggagg ccgcaatcaa agacaacgac tgtgaggagg 
     2761 gcaagggggg catccgaggc ttgtttaaga aggccggcaa actgaacatt accaagccgg 
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     2821 cccctaaaaa agacagcaac atcagcacca tccagtcgat gcacgtcggg gagttcaatc 
     2881 agaagctggt agaagccagc gctcagttta aaaagaaaca gggaaaaggc acgatcgatg 
     2941 tttggtggtt atttgatgat ggagggttga cactgcttat cccatatatc ttgactctca 
     3001 gaaagaaatg gaaagactgt aagttaagaa tctatgttgg aggaaaaatc aaccgcattg 
     3061 aagaggaaaa aatttcaatg gcttctcttc tcagcaaatt taggataaaa tttgcagaca 
     3121 ttcatataat tggagacatc aacattaagc caaacaaaga gagctggaaa gtctttgaag 
     3181 agatgattga accttatagg ctccacgaaa gccacaaaga tttgaccact gctgagaaat 
     3241 taaaaagaga aagtccatgg aaaattacag atgcagaact ggaagcagtc aaggaaaaga 
     3301 gttaccgcca agttcgactg aacgagctgt tacaggagca ttccagagcc gccaacctca 
     3361 tcgtattgag ccttccagtg gcgagaaaag gatctatttc ggatttgttg tacatggcgt 
     3421 ggttagaaat cctgaccaag aacctccctc ctgtgctact ggttagagga aatcacaaga 
     3481 atgtcctgac attttactct taaagcgcga gggatgagaa atgttgtacc ttggtgtccg 
     3541 aataattaca aaacgtgtct ggtactttgt gttttaaaac ctcatctatg aatatacaaa 
     3601 cctctggaga ctatcccacc tgattctaca taaatttcat cttttttaaa aaagttatta 
     3661 ttaatgagag ttttttccca ccagttttaa aaacatcgaa aacatttttc ccttgtcgct 
     3721 ggtgaataag aaattaataa gagctggctg acatgcttgc aggatgtgct aatgtagatg 
     3781 tgagctccag gcaaacgcaa tctcttgttt ccgtggattc tgctgcatgg ccccgtgcag 
     3841 gccacaggcc cacagcgggc tctctttaag ttgttattga cagactggtg tggtgaaagc 
     3901 aggcggctat catagggaaa gacacactgg gtcagtggcc tgattctgct tggcctcctg 
     3961 agaagtttgt ggagatttaa aaatcaatat ccggaaactg taagaaggac tagagtctac 
     4021 aaagtgttca aagcagttac ctaaattaag gtttatttaa tgcagccgat aataagctta 
     4081 acctctgatc acacgtagct tgcatttgct gctagccaga ggtacactag gtaggtgagc 
     4141 aaagacacat gttccactta gacgaaatag agtcccaaca tacaaatatc aattgtcttc 
     4201 ctggttaaat gttttgaaat ttctacctta atactacttt atcttttttc tctgattaag 
     4261 tggtttgcat agacgaaata aaaatagacg atctcattga aaaataatct cacaggtttc 
     4321 caatccacta ctaaaaatat atccagatcc tacatttatt tactttctct atatacaggt 
     4381 atatgggttt tatagaataa caaggatata agtggagaaa cttgtaaaat tttaaaacac 
     4441 aggtgttgat ttttcttctt gttcatgtgt gtataatatt taatcacaga aaaaatgctt 
     4501 atatgataaa tggcttggtt ttggttttgt tggcatattt tgactgttct ggggaagctt 
     4561 gtggggggca aatcaacctg aaataaaatt ctact 
// 
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